🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0014262 Rienhoff syndrome

MONDO models Rienhoff syndrome as a subtype of Loeys-Dietz syndrome (MONDO:0018954) with TGFB3 as the causal gene; exact synonyms include Loeys-Dietz syndrome type 5 (LDS5), and the term carries the OMIM:615582 cross-reference.

📘

Definitions

1

Molecular and clinical diagnosis

The diagnosis is established clinically and/or by identification of a heterozygous pathogenic variant in a Loeys-Dietz gene; TGFB3 is the causal gene for Rienhoff syndrome (Loeys-Dietz syndrome type 5). Because the non-vascular presentation lacks aortic findings entirely, molecular testing rather than the clinical aortic criteria is what establishes the diagnosis at that pole of the spectrum.

DIAGNOSTIC_CRITERIA

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"The diagnosis of LDS is established in (1) a proband with characteristic clinical findings or (2) by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2"

GeneReviews specifies the molecular and clinical basis for establishing the diagnosis, naming TGFB3 among the causal genes.

👪

Inheritance

2

Autosomal dominant inheritance HP:0000006

Rienhoff syndrome is inherited in an autosomal dominant manner. The index case arose from a de novo TGFB3 variant, while subsequent reports describe multigenerational families with variants segregating with the phenotype.

Autosomal dominant inheritance

Show evidence (3 references)

PMID:20301312 SUPPORT Human Clinical

"LDS caused by a pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2 is inherited in an autosomal dominant manner."

GeneReviews states that TGFB3-related Loeys-Dietz syndrome (Rienhoff syndrome / LDS type 5) follows autosomal dominant inheritance.

PMID:29392890 PARTIAL Human Clinical

"Non‐penetrance seems more common in TGFB2/3 families."

Qualifies the autosomal dominant inheritance: penetrance is reduced in TGFB3 families relative to the TGFBR1/2 Loeys-Dietz subtypes, so an obligate carrier may be clinically unaffected. This matters for cascade testing and for interpreting apparently sporadic presentations.

PMID:31898322 SUPPORT Human Clinical

"In familial cases, incomplete penetrance and variable clinical expressivity were noted."

Cohort-level confirmation of incomplete penetrance and variable expressivity within TGFB3 families.

Gene dosage effect (homozygous state) HP:0032113

Although the disorder is autosomal dominant, a single reported homozygous patient had a more severe phenotype than her heterozygous relatives, indicating a gene-dosage effect rather than a strictly dominant all-or-none mechanism. A separate homozygous exon 2-7 deletion patient likewise presented with severe disease including cleft palate. Both are single observations and should not be treated as an established recessive form.

Semidominant inheritance

Show evidence (2 references)

PMID:31898322 SUPPORT Human Clinical

"Our cohort included the first described homozygous patient, who presented with a more severe phenotype compared to her heterozygous relatives."

Directly documents the within-family dosage comparison supporting a gene dosage effect.

PMID:32022420 SUPPORT Human Clinical

"Here, we report the first case of a homozygous TGFB3 variant associated with a severe LDS5 and Marfan-like presentation."

A second, independent homozygous case with severe disease, consistent with a dosage effect.

◈

Mechanistic Hypotheses

2

Paradoxical aortic TGF-beta up-regulation (vasculopathy model)

paradoxical_aortic_tgfb_upregulation CANONICAL

Evidence balance 1 support

In patients with TGFB3-related aortic aneurysm, aortic wall tissue shows paradoxical up-regulation of canonical and non-canonical TGF-beta signalling together with increased TGF-beta ligand expression, mirroring the pattern in TGFBR1/2-, SMAD3- and TGFB2-related disease. Under this model the aortopathy arises from excess, not deficient, aortic TGF-beta signalling. This is the canonical model for the vascular presentation and is the mechanism shared with the `aortopathy_tgfbeta_dysregulation` module.

Pathograph links

Altered TGF-beta Signal Transduction -> Aortic Medial Degeneration and Wall Weakening Dysregulated TGF-beta signalling in the aortic wall drives medial degeneration in the vascular presentation of the syndrome.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"we confirm a paradoxical up-regulation of both canonical and noncanonical TGF-β signaling in association with up-regulation of the expression of TGF-β ligands."

Directly documents increased aortic TGF-beta signalling in TGFB3-variant patients.

Reduced TGF-beta 3 signalling (hypomorphic / dominant negative model)

reduced_tgfb3_signaling ALTERNATIVE

Evidence balance 3 support

In the index patient the TGFB3 p.Cys409Tyr allele encoded a signalling-dead ligand that acted as a dominant negative, reducing canonical and non-canonical TGF-beta signalling. Under this model the phenotype (hypomyoplasia, growth retardation, distal arthrogryposis, bifid uvula, no vascular disease) follows from insufficient TGFB3 activity during mesenchymal development. Recorded as ALTERNATIVE relative to the aortopathy model not because the evidence is weaker - it is direct functional evidence - but because it is the minority explanatory model within the Loeys-Dietz framing and applies to a different allele class and tissue compartment.

Pathograph links

Altered TGF-beta Signal Transduction -> Impaired Mesenchymal Development Reduced TGF-beta 3 signalling during early mesenchymal development impairs myogenesis and palatogenesis.

Show evidence (3 references)

PMID:23824657 SUPPORT Other

"Several lines of evidence indicate the mutation is hypomorphic, suggesting that decreased TGFB signaling from a loss of TGFB3 activity is likely responsible for the clinical phenotype."

States the reduced-signalling conclusion for the index phenotype - the inference neither arm-specific sentence makes on its own. Tagged OTHER because it is the authors' synthesis pooling both functional arms rather than the report of a single experiment; the two items below cite each arm separately so that every experimental item carries one evidence_source.

PMID:23824657 SUPPORT In Vitro

"We conclude that the mutant allele encodes a TGFB3 ligand that is not functional."

The cell-based arm: HEK293T-expressed, immunoprecipitated mutant ligand applied to a p3TP-Lux TGF-beta reporter generated no transcriptional signal, establishing that the p.Cys409Tyr ligand is signalling-dead.

PMID:23824657 SUPPORT Model Organism

"We conclude that in the frog system the mutant TGFB3G1226A allele, when co-expressed with w-t TGFB3, has a dominant negative effect on TGF-β signaling measured by pSMAD2 and pERK1/2, but does not affect signaling by BMP2/4/7 ligands measured by pSMAD1."

The whole-organism arm, and the direct evidence for the dominant-negative claim in this hypothesis description: co-expression with wild-type TGFB3 in Xenopus embryos reduced canonical (pSMAD2) and non-canonical (pERK1/2) signalling while leaving BMP/pSMAD1 signalling intact, showing the effect is specific to the TGF-beta arm rather than general toxicity.

?

Discussions and Knowledge Gaps

4

How can a single gene, TGFB3, produce both a reduced-signalling phenotype with no vascular disease and an aortopathy characterised by paradoxically increased TGF-beta signalling - is the difference allele-specific, tissue-specific, or both?

CONTROVERSY OPEN tgfb3_signaling_direction

Attached to

pathophysiology#Altered TGF-beta Signal Transduction

The two anchor papers for this syndrome reach opposite conclusions about the direction of the signalling defect. Rienhoff et al. showed a signalling-dead, dominant negative p.Cys409Tyr ligand that reduced pSMAD2 and pERK1/2, in a patient with normal echocardiograms through age 8 and no aortic disease. Bertoli-Avella et al. found paradoxical up-regulation of canonical and non-canonical TGF-beta signalling in aortic tissue of TGFB3-variant patients with aneurysms and dissections. A third report notes that the codon 300 (latency-associated peptide domain) variants presumably lead to increased TGF-beta signalling and are associated with tall stature, whereas the Cys409Tyr loss-of-function allele produced growth retardation - suggesting that stature itself may read out the direction of the signalling change. Whether allele class, tissue context, or the well-described paradoxical aortic response to upstream TGF-beta pathway loss reconciles these findings is unresolved, and it directly determines whether TGF-beta-directed therapy would be expected to help or harm a given patient. The strongest reconciling datum so far is that loss-of-function TGFB3 alleles are themselves associated with increased pSMAD2 and CTGF in the aortic media, which points to a tissue-compartment-specific rather than an allele-direction explanation - but that observation has not been paired with matched skeletal-muscle data from the same patients, so it does not close the question.

Proposed experiments

Allele-class by cell-type signalling panel for TGFB3 variants

exp_tgfb3_allele_class_signalling_panel

Assay canonical (pSMAD2/3) and non-canonical (pERK1/2) signalling output for a panel of TGFB3 alleles - cysteine-knot (p.Cys409Tyr), LAP-domain (p.Arg300Gln, p.Arg300Gly) and haploinsufficiency - in matched primary aortic smooth muscle cells and skeletal myoblasts derived from patient induced pluripotent stem cells, to test whether the direction of effect tracks with allele class, with cell type, or with both.

Allele-stratified genotype-phenotype survey of the TGFB3 cohort

exp_tgfb3_genotype_phenotype_stratification

Systematically collect aortic imaging and stature data across the reported TGFB3 cohort stratified by allele class, to test the prediction that LAP-domain variants associate with tall stature and aortopathy while cysteine-knot loss-of-function alleles associate with growth retardation and spared vasculature.

Show evidence (2 references)

PMID:29392890 SUPPORT Human Clinical

"increased pSMAD2 and CTGF expression was observed in the aortic media of patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further confirming the paradoxical observation of increased TGF‐β signaling in vivo"

Shows that loss-of-function TGFB3 alleles nonetheless raise aortic TGF-beta signalling, favouring a tissue-specific over an allele-direction resolution of the controversy.

PMID:26184463 SUPPORT Human Clinical

"The mutations at codon Arg300 presumably lead to increased TGF-beta signalling, suggesting that the short or tall stature seen in patients with TGFB3 mutations may result from opposing effects of mutations on TGF-beta signalling."

Proposes that opposing directions of signalling change explain the opposite growth phenotypes across TGFB3 alleles, framing the controversy.

What is the lifetime aortic risk for an individual carrying a loss-of-function TGFB3 allele who presents with the muscular and skeletal phenotype and has normal aortic imaging in childhood?

KNOWLEDGE GAP OPEN tgfb3_vascular_risk_in_nonvascular_presentation

Attached to

pathophysiology#Progressive Aortic Dilation and Aneurysm

The index patient had yearly echocardiograms from 18 months with normal aortic root dimensions at 6.5 years, and uncertainty about her vascular risk was explicitly named as a principal clinical concern. Because the same gene causes aneurysms and dissections in other families, it is not known whether childhood-normal imaging in a loss-of-function carrier predicts lifelong freedom from aortopathy or merely later onset. This gap has direct surveillance consequences for a rare disorder in which no natural-history cohort spanning both presentations exists.

Proposed experiments

International TGFB3 natural-history registry with protocolised imaging

exp_tgfb3_natural_history_registry

Establish an international TGFB3 registry with protocolised aortic imaging (echocardiography plus whole-arterial-tree magnetic resonance or computed tomography angiography) and longitudinal follow-up, stratified by allele class, to derive age-specific cumulative aortic-event risk for carriers who are imaging-normal in childhood.

Show evidence (2 references)

PMID:23824657 SUPPORT Human Clinical

"The principal clinical concerns for this patient have been growth retardation, weakness related to decreased muscle mass and uncertainty about her risk for vascular disease."

Names the unresolved vascular risk in the non-vascular presentation as an explicit clinical concern.

PMID:23824657 SUPPORT Human Clinical

"The full phenotypic spectrum and natural history of TGFB3 mutations must await other cases"

The authors state explicitly that the natural history is unknown.

Which of the Loeys-Dietz syndrome features catalogued gene-agnostically by GeneReviews - cerebral aneurysm, craniosynostosis, strabismus, the cutaneous triad of velvety translucent skin, easy bruising and dystrophic scars, and the allergic/inflammatory and gastrointestinal predisposition - actually occur in TGFB3-related disease?

KNOWLEDGE GAP OPEN lds_wide_features_not_confirmed_for_tgfb3

Attached to

pathophysiology#Palatal and Craniofacial Malformation

The only GeneReviews chapter covering this disorder is the gene-agnostic Loeys-Dietz syndrome chapter, which pools findings across SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, TGFBR2 and IPO8. The two TGFB3-specific primary sources do not report cerebral aneurysm, craniosynostosis or the allergic/inflammatory phenotype, and the index patient is explicitly described as having skin of normal texture, tension and wound healing - a direct contrast with the LDS cutaneous triad. Arterial tortuosity, a hallmark of other LDS subtypes, is likewise absent from the TGFB3 phenotype. This entry therefore curates only features with TGFB3-specific evidence and does not import the remaining LDS-wide features, but whether their absence reflects genuine gene-specific sparing or merely the small published cohort is unresolved. It matters because gene-agnostic LDS surveillance protocols (for example cerebrovascular imaging) may be either over- or under-inclusive for TGFB3 carriers.

Proposed experiments

Gene-stratified feature audit across the Loeys-Dietz gene panel

exp_tgfb3_gene_specific_feature_audit

Re-analyse existing multicentre Loeys-Dietz cohorts with per-gene stratification and protocolised ascertainment of cerebrovascular imaging, dermatological examination, and allergic/gastrointestinal history, to determine which LDS features are genuinely shared across all causal genes and which are gene-specific. Report TGFB3 carriers separately rather than pooled.

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"Wide variation in the distribution and severity of clinical features can be seen in individuals with LDS, even among affected individuals within a family who have the same pathogenic variant."

GeneReviews itself flags that feature distribution varies widely, which is why LDS-wide features cannot be assumed to apply to TGFB3 carriers.

PMID:23824657 SUPPORT Human Clinical

"Her skin had normal texture, tension, and wound healing."

The index patient explicitly lacked the LDS cutaneous findings, supporting the decision not to import them into this entry.

Does the homozygous Tgfb3-null mouse, the only well-characterised model for this disease, faithfully model a human disorder in which essentially every patient is heterozygous and many alleles are hypomorphic or motif-specific rather than complete nulls?

HUMAN MODEL MISMATCH OPEN tgfb3_mouse_null_vs_human_heterozygote

Attached to

pathophysiology#Impaired Mesenchymal Development pathophysiology#Palatal and Craniofacial Malformation

The dose mismatch is the core issue: the mouse evidence for the palatal mechanism comes from biallelic nulls, whereas human Rienhoff syndrome is autosomal dominant and heterozygous. Human alleles are also mechanistically varied (cysteine-knot disruption, RKKR furin-cleavage-motif disruption, latency-associated peptide domain substitutions), so a complete null is not an obvious surrogate for any of them. The direction of effect diverges too: the mouse null is a pure loss of ligand, while human loss-of-function alleles are associated with increased pSMAD2 in the aortic media. The mouse is nonetheless the strongest available support for the palatogenesis mechanism, and the congenic-background series offers a real mechanistic parallel to human reduced penetrance - so this is a translational-validity caveat on an otherwise well-evidenced node, not an absence of evidence.

Proposed experiments

Allele-matched heterozygous Tgfb3 knock-in mouse series

exp_tgfb3_heterozygous_knockin_mouse

Generate heterozygous mouse lines carrying the orthologous human alleles (cysteine-knot p.Cys409Tyr, an RKKR-motif variant, and a latency-associated peptide domain variant) rather than a null, and phenotype palate, skeletal muscle mass and aortic wall in parallel. Compare each line's SMAD2 phosphorylation in palate, muscle and aorta to test whether one genotype can reproduce both the muscular and the vascular arms of the human disease.

Show evidence (2 references)

PMID:7493021 PARTIAL Model Organism

"Mice lacking TGF-beta 3 exhibit an incompletely penetrant failure of the palatal shelves to fuse leading to cleft palate."

The supporting palatal evidence comes from complete-null mice, not from a heterozygous model matching the human genotype.

PMID:23824657 PARTIAL Human Clinical

"A second de novo mutation was found in TGFB3 (c.1226G>A; pC409Y)."

Confirms the human disease genotype is a heterozygous missense allele, not the biallelic null modelled in mouse.

⚙

Pathophysiology

8

TGFB3 Ligand Variant

Heterozygous variants in TGFB3 alter the transforming growth factor beta 3 ligand. The index p.Cys409Tyr substitution removes the penultimate cysteine of the mature ligand, a residue conserved across the whole TGF-beta family that forms the cysteine knot required for ligand activity. Other reported alleles cluster in the latency-associated peptide domain (p.Arg300Gln, p.Arg300Gly). This is the conserved genetic trigger for the syndrome.

transforming growth factor beta receptor signaling pathway GO:0007179 ⚠ ABNORMAL

Downstream

Altered TGF-beta Signal Transduction The variant ligand changes the amount of TGF-beta signal delivered to target tissues.

Show evidence (2 references)

PMID:23824657 SUPPORT Human Clinical

"A de novo mutation in TGFB3 was identified by exome sequencing."

Identifies a de novo TGFB3 variant as the causal lesion in the index patient.

PMID:23824657 SUPPORT Other

"This penultimate cysteine is conserved in all TGFB family member ligands including orthologues in Caenorhabditis elegans and Drosophila melanogaster defining a structure called the “cysteine knot”, a conformation essential for normal ligand activity"

Explains why loss of Cys409 abolishes ligand function: it destroys the cysteine knot required for TGF-beta ligand activity. Tagged OTHER because within this publication the statement is a structural/literature assertion citing prior crystallographic work (Daopin 1992, Mittl 1996), not an experiment reported in this paper.

Altered TGF-beta Signal Transduction

TGFB3 variants perturb canonical (SMAD2/3) and non-canonical (ERK1/2) TGF-beta signal transduction. The direction of the perturbation is allele- and tissue-dependent and is the central unresolved issue of the syndrome. In the index case the mutant ligand was signalling-dead and behaved as a dominant negative, reducing SMAD2 and ERK1/2 phosphorylation to roughly 40% and 60% of wild-type levels. In contrast, aortic wall tissue from patients with TGFB3-related aortic aneurysm shows paradoxical up-regulation of both canonical and non-canonical TGF-beta signalling, exactly as seen for variants in TGFBR1/2, SMAD3 and TGFB2.

Paradoxical aortic TGF-beta up-regulation (vasculopathy model) Reduced TGF-beta 3 signalling (hypomorphic / dominant negative model)

SMAD protein signal transduction GO:0060395 ⚠ ABNORMAL

Downstream

Impaired Mesenchymal Development Reduced TGF-beta 3 signalling during early mesenchymal development impairs myogenesis and palatogenesis.

Aortic Medial Degeneration and Wall Weakening Dysregulated TGF-beta signalling in the aortic wall drives medial degeneration in the vascular presentation of the syndrome.

Show evidence (3 references)

PMID:23824657 SUPPORT Model Organism

"A 1:1 ratio of mutant-to-wild-type TGFB3 RNA diminished the pSMAD2 and pERK1/2 signals to approximately 40% and 60%, respectively, of that generated by the w-t TGFB3 RNA alone."

Quantifies the dominant negative reduction of canonical (pSMAD2) and non-canonical (pERK1/2) TGF-beta signalling by the index allele in Xenopus embryos.

PMID:25835445 PARTIAL Human Clinical

"we confirm a paradoxical up-regulation of both canonical and noncanonical TGF-β signaling in association with up-regulation of the expression of TGF-β ligands."

Documents the opposite direction of effect in aortic tissue from TGFB3-variant patients, supporting the node as "altered" signalling while leaving the direction allele- and tissue-dependent.

PMID:29392890 SUPPORT Human Clinical

"increased pSMAD2 and CTGF expression was observed in the aortic media of patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further confirming the paradoxical observation of increased TGF‐β signaling in vivo"

Key reconciling observation: the very same loss-of-function TGFB3 alleles produce increased pSMAD2 and CTGF in the aortic media. This argues the apparent contradiction between the reduced-signalling and increased-signalling models is tissue-compartment-specific rather than a simple allele-direction difference.

Impaired Mesenchymal Development

TGF-beta 3 is the most abundant TGF-beta isoform in developing skeletal muscle and is required for the epithelial-to-mesenchymal transition of the dermomyotome that generates myogenic precursors, and for confluence of the palatal shelves. Insufficient TGFB3 signalling at these stages is proposed to reduce the pool of embryonic muscle precursor cells - producing hypomyoplasia with normal muscle architecture rather than a myopathy - and to prevent complete palatal fusion.

epithelial to mesenchymal transition GO:0001837 ↓ DECREASED

Downstream

Hypomyoplasia and Growth Failure A reduced embryonic muscle precursor pool yields low post-natal muscle mass and impaired somatic growth.

Palatal and Craniofacial Malformation Failure of palatal shelf confluence produces bifid uvula and cleft palate.

Show evidence (2 references)

PMID:23824657 PARTIAL Other

"Partial or incomplete EMT may diminish the number of embryonic muscle precursor cells, ultimately reducing post-natal myofibril mass but not affecting muscle architecture."

States the proposed cellular mechanism linking reduced TGFB3 signalling to hypomyoplasia with preserved muscle architecture. Downgraded to PARTIAL/OTHER because the authors frame this as a hypothesis ("may diminish") built on developmental-biology literature rather than an observation in their patient; the preserved muscle architecture it predicts is separately evidenced by the muscle biopsy.

PMID:23824657 SUPPORT Human Clinical

"TGFB3 is essential for both human palatogenesis and normal muscle growth."

Establishes the two mesenchymal developmental programs that require TGFB3.

Hypomyoplasia and Growth Failure

The muscular phenotype is a developmental deficiency of muscle mass (hypomyoplasia) rather than a degenerative myopathy. Muscle biopsy in the index patient showed essentially normal fibre size and architecture with no dystrophic, inflammatory or fibrotic change, sharply distinguishing it from the myopathy of Marfan syndrome. Reduced fetal movement from this deficit is the proposed origin of the distal arthrogryposis present at birth.

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"Distal arthrogryposis indicative of reduced fetal movement suggested an inborn error of development affecting muscle mass and other developing mesenchymal tissues, including the soft palate."

Links the arthrogryposis to reduced fetal movement caused by the developmental muscle deficit.

Palatal and Craniofacial Malformation

Failure of complete palatal fusion produces the bifid uvula and cleft palate that are among the most consistent findings across the TGFB3 phenotypic spectrum, together with hypertelorism and other craniofacial features shared with Loeys-Dietz and Shprintzen-Goldberg syndromes.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"Other systemic features overlap clinically with Loeys-Dietz, Shprintzen-Goldberg, and Marfan syndromes, including cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity."

Documents the craniofacial and skeletal feature set in the TGFB3 cohort.

Aortic Medial Degeneration and Wall Weakening

In the vascular presentation, dysregulated TGF-beta signalling in the aortic wall drives medial degeneration and loss of wall integrity, the shared tissue-level lesion of the TGF-beta vasculopathies. Notably, and unlike other Loeys-Dietz subtypes, striking aortic or arterial tortuosity is not part of the TGFB3 phenotype.

Downstream

Progressive Aortic Dilation and Aneurysm A weakened media dilates progressively under haemodynamic load.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"In line with previous observations in aortic wall tissues of patients with mutations in effectors of TGF-β signaling (TGFBR1/2, SMAD3, and TGFB2), we confirm a paradoxical up-regulation of both canonical and noncanonical TGF-β signaling"

Places TGFB3-related aortic disease in the same aortic-wall TGF-beta dysregulation family as the other Loeys-Dietz genes.

Progressive Aortic Dilation and Aneurysm

Aneurysmal dilation affects the thoracic and/or abdominal aorta and carries a risk of dissection and rupture, making early recognition of TGFB3 carriers clinically important.

Downstream

Aortic Dissection and Rupture Progressive dilation culminates in dissection or rupture.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"We demonstrate that TGFB3 mutations are associated with significant cardiovascular involvement, including thoracic/abdominal aortic aneurysm and dissection, and mitral valve disease."

Establishes thoracic and abdominal aortic aneurysm as a core feature of TGFB3-related disease.

Aortic Dissection and Rupture

Dissection or rupture of the dilated aorta is the principal cause of mortality in the vascular presentation of the syndrome, and the reason early molecular diagnosis and surveillance matter.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"Our findings emphasize the broad clinical variability associated with TGFB3 mutations and highlight the importance of early recognition of the disease because of high cardiovascular risk."

States the high cardiovascular risk that motivates early recognition.

✶

Histopathology

1

Hypomyoplasia with Preserved Muscle Architecture

Quadriceps muscle biopsy in the index patient showed a normal checkerboard pattern with type 1 fibre predominance and only mild, focal type 1 fibre disproportion consistent with disuse. Critically, there was no endomysial thickening, fat deposition, fibre splitting or fibrosis - the changes that characterise the myopathy of Marfan syndrome - establishing the muscle lesion as a developmental deficiency of muscle mass rather than a degenerative myopathy.

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"A muscle biopsy showed essentially normal fiber size and architecture. There was no evidence of chronic dystrophic or inflammatory changes presenting a strikingly different histologic picture compared to the myopathic findings in congenital or classical MFS"

Direct human muscle histology distinguishing TGFB3-related hypomyoplasia from Marfan myopathy.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

25

Cardiovascular 2

Aortic Dissection Aortic dissection HP:0002647

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"including thoracic/abdominal aortic aneurysm and dissection"

Documents aortic dissection as part of the TGFB3 cardiovascular phenotype.

Aortic Root Dilatation OCCASIONAL Aortic root aneurysm HP:0002616

Show evidence (1 reference)

PMID:31898322 SUPPORT Human Clinical

"Aortic root dilatation and mitral valve disease represented the most common cardiovascular findings, reported in 29% and 32% of patients, respectively."

Quantifies aortic root dilatation at 29% in a 32-patient TGFB3 cohort, mapping to OCCASIONAL (5-29%).

Eye 2

Hypertelorism Hypertelorism HP:0000316

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"She was hyperteloric and had a bifid uvula, the two non-vascular findings that define LDS"

Documents hypertelorism in the index patient.

Blue Sclerae Blue sclerae HP:0000592

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"The sclerae were blue."

Direct documentation of blue sclerae on examination.

Head and Neck 3

Bifid Uvula Bifid uvula HP:0000193

Show evidence (2 references)

PMID:23824657 SUPPORT Human Clinical

"We describe a syndrome presenting at birth with distal arthrogryposis, hypotonia, bifid uvula, a failure of normal post-natal muscle development without evidence of vascular disease"

Bifid uvula was present at birth in the index patient.

PMID:25835445 SUPPORT Human Clinical

"including cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity"

Bifid uvula recurs in the independent TGFB3 aortopathy cohort.

Cleft Palate Cleft palate HP:0000175

Show evidence (2 references)

PMID:25835445 SUPPORT Human Clinical

"including cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity"

Documents cleft palate in the TGFB3 cohort.

PMID:23824657 SUPPORT Human Clinical

"TGFB3 is essential for both human palatogenesis and normal muscle growth."

Establishes the causal requirement for TGFB3 in palatogenesis underlying the palatal phenotype.

High Palate FREQUENT High palate HP:0000218

Show evidence (1 reference)

PMID:31898322 SUPPORT Human Clinical

"A high frequency of systemic features (65% high-arched palate, 63% arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was observed."

Quantifies high-arched palate at 65% in a 32-patient, 17-family TGFB3 cohort, mapping to FREQUENT (30-79%).

Limbs 3

Talipes Equinovarus Talipes equinovarus HP:0001762

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"including cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity"

Documents clubfoot deformity in the TGFB3 cohort.

Arachnodactyly FREQUENT Arachnodactyly HP:0001166

Show evidence (3 references)

PMID:31898322 SUPPORT Human Clinical

"A high frequency of systemic features (65% high-arched palate, 63% arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was observed."

Quantifies arachnodactyly at 63% in the TGFB3 cohort, mapping to FREQUENT (30-79%).

PMID:23824657 SUPPORT Human Clinical

"the skeletal findings typical of MFS included arachnodactyly, pectus excavatum, pes planus, and hyperextensible large joints"

Documents arachnodactyly among the Marfanoid skeletal findings in the index patient.

PMID:26184463 SUPPORT Human Clinical

"had tall stature, arachnodactyly, hyperextensible joints, hypertelorism, bifid uvula"

Arachnodactyly recurs in an independent TGFB3 family.

Pes Planus Pes planus HP:0001763

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"Also noted was bilateral pes planus, mild pectus excavatum, hyperextensibility of multiple large joints, and mild retrognathia."

Documents bilateral pes planus in the index patient.

Musculoskeletal 4

Scoliosis Scoliosis HP:0002650

Show evidence (1 reference)

PMID:32022420 SUPPORT Human Clinical

"musculoskeletal abnormalities-severe scoliosis, joint laxity, long digits, flat feet, decreased muscle mass, and diminished muscle strength"

Documents severe scoliosis in a TGFB3 patient, though in the more severely affected homozygous state rather than the typical heterozygous presentation.

Joint Hypermobility FREQUENT Joint hypermobility HP:0001382

Show evidence (2 references)

PMID:31898322 SUPPORT Human Clinical

"A high frequency of systemic features (65% high-arched palate, 63% arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was observed."

Quantifies joint hypermobility at 52% in the TGFB3 cohort, mapping to FREQUENT (30-79%).

PMID:23824657 SUPPORT Human Clinical

"The skin had normal texture, subcutaneous fat was minimal, and marked hyperextensibility was present in elbows and knees."

Documents marked large-joint hyperextensibility in the index patient.

Pectus Excavatum Pectus excavatum HP:0000767

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"the skeletal findings typical of MFS included arachnodactyly, pectus excavatum, pes planus, and hyperextensible large joints"

Documents pectus excavatum in the index patient.

Hypotonia Hypotonia HP:0001252

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"There was a midline facial nevus flammeus and mild hypotonia."

Hypotonia documented on the newborn physical examination.

Nervous System 1

Motor Delay Motor delay HP:0001270

Show evidence (2 references)

PMID:23824657 SUPPORT Human Clinical

"An evaluation at 17 months showed that she did not crawl or roll, but could stand with support."

Direct documentation of markedly delayed gross motor milestones in the index patient.

PMID:23824657 SUPPORT Human Clinical

"Her neurocognitive development was appropriate for age."

Confirms the delay was motor rather than cognitive, consistent with a primary muscle deficit rather than a neurodevelopmental disorder.

Growth 2

Growth Delay Growth delay HP:0001510

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"At age 3 months, the patient was evaluated for failure-to-thrive because of low weight (4.2 kg <5th centile) and a delay in gross motor function."

Documents early growth failure in the index patient.

Tall Stature Tall stature HP:0000098

Show evidence (1 reference)

PMID:26184463 SUPPORT Human Clinical

"The two affected children and their affected father had tall stature, arachnodactyly, hyperextensible joints, hypertelorism, bifid uvula, but no cardiac involvement"

Documents tall stature in a three-generation family with the TGFB3 p.Arg300Gly variant.

Other 8

Thoracic Aortic Aneurysm Thoracic aortic aneurysm HP:0012727

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"We demonstrate that TGFB3 mutations are associated with significant cardiovascular involvement, including thoracic/abdominal aortic aneurysm and dissection, and mitral valve disease."

Documents thoracic aortic aneurysm in the 43-patient TGFB3 cohort.

Abdominal Aortic Aneurysm Abdominal aortic aneurysm HP:0005112

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"including thoracic/abdominal aortic aneurysm and dissection"

Explicitly includes abdominal aortic aneurysm in the TGFB3 phenotype.

Mitral Valve Disease FREQUENT Abnormal mitral valve morphology HP:0001633

Show evidence (2 references)

PMID:31898322 SUPPORT Human Clinical

"Aortic root dilatation and mitral valve disease represented the most common cardiovascular findings, reported in 29% and 32% of patients, respectively."

Quantifies mitral valve disease at 32% in the TGFB3 cohort, mapping to FREQUENT (30-79%).

PMID:25835445 SUPPORT Human Clinical

"significant cardiovascular involvement, including thoracic/abdominal aortic aneurysm and dissection, and mitral valve disease"

Lists mitral valve disease among the significant cardiovascular manifestations of TGFB3 variants.

Retrognathia Retrognathia HP:0000278

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"Also noted was bilateral pes planus, mild pectus excavatum, hyperextensibility of multiple large joints, and mild retrognathia."

Documents retrognathia in the index patient.

Distal Arthrogryposis Distal arthrogryposis HP:0005684

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"We describe a syndrome presenting at birth with distal arthrogryposis, hypotonia, bifid uvula, a failure of normal post-natal muscle development without evidence of vascular disease"

Distal arthrogryposis was present at birth in the index patient.

Decreased Muscle Mass Decreased muscle mass HP:0003199

Show evidence (2 references)

PMID:23824657 SUPPORT Human Clinical

"Her motor examination revealed decreased bulk in all appendicular and axial muscles, strength 1/5, low tone, and diminished reflexes throughout."

Direct clinical documentation of reduced muscle bulk and weakness in the index patient.

PMID:32022420 SUPPORT Human Clinical

"musculoskeletal abnormalities-severe scoliosis, joint laxity, long digits, flat feet, decreased muscle mass, and diminished muscle strength"

Independent corroboration of decreased muscle mass and strength in a second, unrelated TGFB3 patient (homozygous exon 2-7 deletion), which matters because the muscular phenotype was otherwise supported only by the single index case.

Cervical Spine Instability Cervical instability HP:0008462

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"including cleft palate, bifid uvula, skeletal overgrowth, cervical spine instability and clubfoot deformity"

Documents cervical spine instability in the TGFB3 cohort.

Pectus Deformity FREQUENT Abnormal sternum morphology HP:0000766

Show evidence (1 reference)

PMID:31898322 SUPPORT Human Clinical

"A high frequency of systemic features (65% high-arched palate, 63% arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was observed."

Quantifies pectus deformity at 57% in the TGFB3 cohort, mapping to FREQUENT (30-79%). The cohort reports "pectus deformity" without specifying excavatum versus carinatum, so the generic sternal term is used here.

🧬

Genetic Associations

1

TGFB3 (Causative)

Gene: TGFB3 hgnc:11769 relationship_type: CAUSATIVE

Show evidence (7 references)

PMID:23824657 SUPPORT Human Clinical

"A second de novo mutation was found in TGFB3 (c.1226G>A; pC409Y). Validation by Sanger sequencing confirmed that this mutation was de novo in the proband."

Identifies and validates the causal de novo TGFB3 variant in the index patient.

PMID:25835445 SUPPORT Human Clinical

"Here, we report on 43 patients from 11 families with syndromic presentations of aortic aneurysms caused by TGFB3 mutations."

Establishes TGFB3 as a cause of syndromic aortic aneurysm across multiple independent families.

PMID:26184463 SUPPORT Human Clinical

"We detected a novel heterozygous mutation in TGFB3, c.898C>G, predicting the missense substitution p.Arg300Gly. Sanger sequencing confirmed the mutation and its segregation with the phenotype."

Documents a second allele class with familial segregation, supporting autosomal dominant TGFB3-related disease.

+ 4 more references

💊

Medical Actions

8

Arterial-Tree Imaging Surveillance

Category: Monitoring Action: supportive care Ontology label: Supportive Care NCIT:C15747

Serial echocardiography of the aortic root and ascending aorta together with magnetic resonance or computed tomography angiography of the entire arterial tree. Because TGFB3-related disease involves the abdominal as well as the thoracic aorta, surveillance cannot be confined to the aortic root.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Echocardiography to monitor the status of the aortic root and ascending aorta (at least annually) and magnetic resonance angiography or computerized tomography angiography to assess the entire arterial tree"

GeneReviews specifies the whole-arterial-tree surveillance regimen for Loeys-Dietz syndrome, which includes TGFB3-related LDS type 5.

Beta-Adrenergic Blocker Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: beta-adrenergic antagonist NCIT:C29576

Beta-adrenergic receptor blockers reduce haemodynamic stress on the aortic wall with the aim of slowing aneurysm progression.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"

GeneReviews documents beta-adrenergic receptor blockade to reduce haemodynamic stress in Loeys-Dietz syndrome.

Angiotensin Receptor Blocker Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: losartan CHEBI:6541

Angiotensin receptor blockers such as losartan are used to reduce haemodynamic stress in Loeys-Dietz syndrome. Their role in Rienhoff syndrome is uncertain and direction-dependent: a three-year trial of losartan in the index patient produced no change in muscle strength or mass, consistent with a pathophysiology of reduced rather than excess TGF-beta signalling in that allele class.

Show evidence (2 references)

PMID:20301312 SUPPORT Human Clinical

"angiotensin receptor blockers, beta-adrenergic receptor blockers, or other medications are used to reduce hemodynamic stress"

GeneReviews documents angiotensin receptor blockade for haemodynamic stress reduction in Loeys-Dietz syndrome.

PMID:23824657 REFUTE Human Clinical

"At age 3 years, a 3-year trial of losartan at a dose of up to 2.0 mg/kg/day produced no change in muscle strength or mass"

A prolonged losartan trial failed to improve the muscular phenotype in the index patient, arguing against TGF-beta blockade for the reduced-signalling presentation.

Prophylactic Aortic Surgery

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Aneurysms are amenable to early and aggressive surgical repair; prophylactic intervention at appropriate thresholds prevents dissection and rupture.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"aneurysms are amenable to early and aggressive surgical intervention"

GeneReviews documents early aggressive surgical repair of aneurysms in Loeys-Dietz syndrome.

Physical and Occupational Therapy

Action: physical therapy Ontology label: Physical Therapy NCIT:C15302

Physical and occupational therapy with orthotic support addresses the contractures, hypotonia and motor delay of the muscular presentation. The index patient received both from six months of age and wore foot orthoses from age two, retaining functional hand use despite persistent digit contractures.

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"The proband had physical and occupational therapy since the age 6 months, and has worn orthotic foot appliances since age 2. Although digit contractures persist, at age 9 she has very functional hands."

Documents the rehabilitative management and its functional outcome in the index patient.

Activity Restriction and Avoidance of Cardiovascular Stimulants

Action: supportive care Ontology label: Supportive Care NCIT:C15747

Individuals with Loeys-Dietz syndrome are advised to avoid contact and competitive sports and isometric exercise, and agents that stimulate the cardiovascular system including routine decongestants and triptans for migraine. This is the LDS-wide "agents/circumstances to avoid" guidance; it applies to TGFB3 carriers with demonstrated aortic involvement, and its applicability to the non-vascular presentation with normal serial imaging has not been separately studied.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Agents/circumstances to avoid: Contact sports, competitive sports, and isometric exercise; agents that stimulate the cardiovascular system including routine use of decongestants or triptan medications for the management of migraine headache"

GeneReviews lists the activities and agents to avoid in Loeys-Dietz syndrome, which includes TGFB3-related LDS type 5.

Pregnancy and Peripartum Aortic Surveillance

Category: Monitoring Action: supportive care Ontology label: Supportive Care NCIT:C15747

Pregnancy and the postpartum period are high-risk intervals in Loeys-Dietz syndrome, with increased risk of aortic dissection or rupture and of uterine rupture, so aortic imaging is intensified during gestation and in the weeks after delivery and medical therapy is reviewed for fetal safety.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Pregnancy and the postpartum period can be dangerous for women with LDS because of increased risk of aortic dissection/rupture and uterine rupture. Increased frequency of aortic imaging is recommended, both during pregnancy and in the weeks following delivery."

GeneReviews documents the peripartum aortic-catastrophe and uterine-rupture risk in Loeys-Dietz syndrome and the intensified imaging schedule it warrants.

Genetic Counseling

Category: Counseling / Informational Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Autosomal dominant inheritance with a 50% recurrence risk for offspring, and a high de novo rate among Loeys-Dietz probands, make genetic counseling and cascade testing of at-risk relatives central to management.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"Each child of an individual with LDS has a 50% chance of inheriting the pathogenic variant and the disorder."

GeneReviews states the recurrence risk that underpins genetic counseling.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Rienhoff Syndrome:

Marfan syndrome MONDO:0007947

Overlapping Features Shares aortic aneurysm, arachnodactyly, pectus deformity, pes planus, joint hyperextensibility and low muscle mass. The index Rienhoff patient was explicitly evaluated against and did not meet Marfan diagnostic criteria.

Distinguishing Features

Marfan syndrome is caused by FBN1 variants and features ectopia lentis, which is not part of the TGFB3 phenotype.
Bifid uvula and cleft palate point away from Marfan and toward the Loeys-Dietz spectrum.
The muscle histopathology differs decisively: Marfan myopathy shows endomysial thickening, fat deposition, split fibres and fibrosis, whereas TGFB3-related hypomyoplasia shows essentially normal fibre size and architecture.

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"The proposita did not meet the diagnostic criteria established for MFS, BHS or LDS."

Documents that the index patient was assessed against, and failed to meet, Marfan, Beals-Hecht and Loeys-Dietz criteria.

Loeys-Dietz syndrome (other genetic subtypes) MONDO:0018954

Overlapping Features The TGFBR1-, TGFBR2-, SMAD2-, SMAD3-, TGFB2- and IPO8-related subtypes share hypertelorism, bifid uvula/cleft palate, skeletal features and aortic aneurysm, and are distinguished only by molecular testing.

Distinguishing Features

Striking aortic and arterial tortuosity, characteristic of the other Loeys-Dietz subtypes, is not present in TGFB3-related disease.
TGFB3-related disease uniquely encompasses a non-vascular pole with hypomyoplasia and distal arthrogryposis.
Definitive discrimination requires identification of the causal gene.

Show evidence (1 reference)

PMID:20301312 SUPPORT Human Clinical

"by the identification of a heterozygous pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2"

Molecular testing across the Loeys-Dietz gene panel is what discriminates the subtypes, since their clinical features overlap.

Beals-Hecht syndrome (congenital contractural arachnodactyly) Not Yet Curated MONDO:0007363

Overlapping Features Shares congenital contractures, arachnodactyly and low muscle mass with the non-vascular presentation of Rienhoff syndrome, and was formally considered in the differential for the index patient.

Distinguishing Features

Beals-Hecht syndrome is caused by FBN2 variants and characteristically includes crumpled ears; the index Rienhoff patient had normally placed, well-formed ears and did not meet Beals-Hecht criteria.

Show evidence (1 reference)

PMID:23824657 SUPPORT Human Clinical

"The proband shared the clinical feature of low muscle mass with hypotonia with three related conditions: Marfan, Loeys–Dietz, and Beals–Hecht syndrome (BHS, OMIM # 121050)."

Names Beals-Hecht syndrome as a formal differential for the index presentation.

Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1) Not Yet Curated MONDO:0007152

Overlapping Features A mechanistically and clinically distinct disease caused by variants in the same gene. ARVD1 arises from TGFB3 *regulatory* variants in the untranslated regions that increase TGFB3 expression, and manifests as fibrofatty replacement of right ventricular myocardium with arrhythmia and sudden-death risk - not as a connective tissue or aortic disorder. Included here as a curation guard: TGFB3 gene-disease assertions must be attributed to the correct entity, since a coding-region variant implies Rienhoff syndrome while a regulatory-region variant implies ARVD1.

Distinguishing Features

ARVD1 is caused by regulatory (untranslated-region) TGFB3 variants that increase promoter/UTR activity, whereas Rienhoff syndrome is caused by coding-region variants altering the ligand itself.
ARVD1 presents with right ventricular fibrofatty replacement, ventricular arrhythmia and sudden death, without the craniofacial, skeletal or aortic-aneurysm features of Rienhoff syndrome.

Show evidence (2 references)

PMID:15639475 SUPPORT Human Clinical

"We identified TGFbeta3 as the disease gene involved in ARVD1."

Establishes TGFB3 as the ARVD1 gene, a separate disease entity from Rienhoff syndrome despite the shared locus.

PMID:15639475 SUPPORT In Vitro

"In vitro expression assays with constructs containing the mutations showed that mutated UTRs were twofold more active than wild-types."

Shows the ARVD1 mechanism is increased expression driven by regulatory variants, distinct from the coding-variant ligand defect of Rienhoff syndrome.

Shprintzen-Goldberg syndrome MONDO:0008426

Overlapping Features A marfanoid craniosynostosis syndrome whose systemic features overlap those of TGFB3-related disease, explicitly named in the TGFB3 cohort report.

Distinguishing Features

Shprintzen-Goldberg syndrome is caused by SKI variants and characteristically includes craniosynostosis and intellectual disability, neither of which is documented in TGFB3-related disease; the index Rienhoff patient had age-appropriate neurocognitive development.

Show evidence (1 reference)

PMID:25835445 SUPPORT Human Clinical

"Other systemic features overlap clinically with Loeys-Dietz, Shprintzen-Goldberg, and Marfan syndromes"

Names Shprintzen-Goldberg syndrome among the syndromes whose systemic features overlap TGFB3-related disease.

{ }

Source YAML

click to show

name: Rienhoff Syndrome
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
description: >
  Rienhoff syndrome, also designated Loeys-Dietz syndrome type 5 (LDS5), is a
  rare autosomal dominant connective tissue disorder caused by heterozygous
  variants in TGFB3, the gene encoding the transforming growth factor beta 3
  ligand. It occupies an unusual position within the heritable thoracic aortic
  disease spectrum because the reported phenotype is strikingly bimodal. The
  index patient (Rienhoff et al., 2013) presented at birth with distal
  arthrogryposis, hypotonia, bifid uvula, marked growth retardation and a
  failure of normal post-natal muscle development, but with no vascular disease;
  the causal p.Cys409Tyr allele was shown to be a signalling-dead, dominant
  negative ligand that reduces TGF-beta signalling. Two years later a large
  multicentre study (Bertoli-Avella et al., 2015) described 43 patients from 11
  families in whom TGFB3 variants caused syndromic thoracic and abdominal aortic
  aneurysms and dissections with mitral valve disease, alongside craniofacial
  and skeletal features overlapping Loeys-Dietz, Shprintzen-Goldberg and Marfan
  syndromes (cleft palate, bifid uvula, skeletal overgrowth, cervical spine
  instability and clubfoot). Unlike other Loeys-Dietz subtypes, striking aortic
  or arterial tortuosity is not a feature. The syndrome therefore spans a
  muscular and skeletal presentation without vascular disease at one pole and a
  high-cardiovascular-risk aortopathy at the other, and the reconciliation of
  the reduced-signalling and paradoxically-increased-signalling models remains
  an open mechanistic question.
disease_term:
  preferred_term: Rienhoff syndrome
  term:
    id: MONDO:0014262
    label: Rienhoff syndrome
synonyms:
- Loeys-Dietz syndrome type 5
- Loeys-Dietz syndrome 5
- LDS5
- TGFB3-related Loeys-Dietz syndrome
classifications:
  harrisons_chapter:
  - classification_value: CARDIOVASCULAR
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
  isds_skeletal_category:
  - classification_value: overgrowth_syndromes_with_skeletal_involvement
    notes: >-
      ISDS Nosology and Classification of Genetic Skeletal Disorders, 2019
      revision (Mortier et al., PMID:31633310), Table 1 group 30 "Overgrowth (tall
      stature) syndromes with skeletal involvement"; listed as "Loeys-Dietz
      syndrome (types 1-6), the TGFB3 locus".
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0014262
      label: Rienhoff syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO models Rienhoff syndrome as a subtype of Loeys-Dietz syndrome
      (MONDO:0018954) with TGFB3 as the causal gene; exact synonyms include
      Loeys-Dietz syndrome type 5 (LDS5), and the term carries the OMIM:615582
      cross-reference.
definitions:
- name: Molecular and clinical diagnosis
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    The diagnosis is established clinically and/or by identification of a
    heterozygous pathogenic variant in a Loeys-Dietz gene; TGFB3 is the causal
    gene for Rienhoff syndrome (Loeys-Dietz syndrome type 5). Because the
    non-vascular presentation lacks aortic findings entirely, molecular testing
    rather than the clinical aortic criteria is what establishes the diagnosis
    at that pole of the spectrum.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The diagnosis of LDS is established in (1) a proband with characteristic
      clinical findings or (2) by the identification of a heterozygous
      pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2
    explanation: >-
      GeneReviews specifies the molecular and clinical basis for establishing
      the diagnosis, naming TGFB3 among the causal genes.
references:
- reference: PMID:20301312
  title: "Loeys-Dietz Syndrome."
  tags:
  - GeneReviews
inheritance:
- name: Autosomal dominant inheritance
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Rienhoff syndrome is inherited in an autosomal dominant manner. The index
    case arose from a de novo TGFB3 variant, while subsequent reports describe
    multigenerational families with variants segregating with the phenotype.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LDS caused by a pathogenic variant in SMAD2, SMAD3, TGFB2, TGFB3, TGFBR1,
      or TGFBR2 is inherited in an autosomal dominant manner.
    explanation: >-
      GeneReviews states that TGFB3-related Loeys-Dietz syndrome (Rienhoff
      syndrome / LDS type 5) follows autosomal dominant inheritance.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Non‐penetrance seems more common in TGFB2/3 families.
    explanation: >-
      Qualifies the autosomal dominant inheritance: penetrance is reduced in
      TGFB3 families relative to the TGFBR1/2 Loeys-Dietz subtypes, so an
      obligate carrier may be clinically unaffected. This matters for cascade
      testing and for interpreting apparently sporadic presentations.
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In familial cases, incomplete penetrance and variable clinical
      expressivity were noted.
    explanation: >-
      Cohort-level confirmation of incomplete penetrance and variable
      expressivity within TGFB3 families.
- name: Gene dosage effect (homozygous state)
  inheritance_term:
    preferred_term: Semidominant inheritance
    term:
      id: HP:0032113
      label: Semidominant inheritance
  description: >-
    Although the disorder is autosomal dominant, a single reported homozygous
    patient had a more severe phenotype than her heterozygous relatives,
    indicating a gene-dosage effect rather than a strictly dominant all-or-none
    mechanism. A separate homozygous exon 2-7 deletion patient likewise
    presented with severe disease including cleft palate. Both are single
    observations and should not be treated as an established recessive form.
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our cohort included the first described homozygous patient, who presented
      with a more severe phenotype compared to her heterozygous relatives.
    explanation: >-
      Directly documents the within-family dosage comparison supporting a gene
      dosage effect.
  - reference: PMID:32022420
    reference_title: "Homozygous deletion of exons 2-7 within TGFB3 gene in a child with severe Loeys-Dietz syndrome and Marfan-like features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report the first case of a homozygous TGFB3 variant associated
      with a severe LDS5 and Marfan-like presentation.
    explanation: >-
      A second, independent homozygous case with severe disease, consistent
      with a dosage effect.
pathophysiology:
- name: TGFB3 Ligand Variant
  biological_scale: MOLECULAR
  description: >-
    Heterozygous variants in TGFB3 alter the transforming growth factor beta 3
    ligand. The index p.Cys409Tyr substitution removes the penultimate cysteine
    of the mature ligand, a residue conserved across the whole TGF-beta family
    that forms the cysteine knot required for ligand activity. Other reported
    alleles cluster in the latency-associated peptide domain (p.Arg300Gln,
    p.Arg300Gly). This is the conserved genetic trigger for the syndrome.
  biological_processes:
  - preferred_term: transforming growth factor beta receptor signaling pathway
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
    modifier: ABNORMAL
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A de novo mutation in TGFB3 was identified by exome sequencing.
    explanation: >-
      Identifies a de novo TGFB3 variant as the causal lesion in the index
      patient.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This penultimate cysteine is conserved in all TGFB family member ligands
      including orthologues in Caenorhabditis elegans and Drosophila
      melanogaster defining a structure called the “cysteine knot”, a
      conformation essential for normal ligand activity
    explanation: >-
      Explains why loss of Cys409 abolishes ligand function: it destroys the
      cysteine knot required for TGF-beta ligand activity. Tagged OTHER because
      within this publication the statement is a structural/literature
      assertion citing prior crystallographic work (Daopin 1992, Mittl 1996),
      not an experiment reported in this paper.
  downstream:
  - target: Altered TGF-beta Signal Transduction
    description: >-
      The variant ligand changes the amount of TGF-beta signal delivered to
      target tissues.
- name: Altered TGF-beta Signal Transduction
  biological_scale: MOLECULAR
  conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation"
  description: >-
    TGFB3 variants perturb canonical (SMAD2/3) and non-canonical (ERK1/2)
    TGF-beta signal transduction. The direction of the perturbation is
    allele- and tissue-dependent and is the central unresolved issue of the
    syndrome. In the index case the mutant ligand was signalling-dead and
    behaved as a dominant negative, reducing SMAD2 and ERK1/2 phosphorylation
    to roughly 40% and 60% of wild-type levels. In contrast, aortic wall tissue
    from patients with TGFB3-related aortic aneurysm shows paradoxical
    up-regulation of both canonical and non-canonical TGF-beta signalling,
    exactly as seen for variants in TGFBR1/2, SMAD3 and TGFB2.
  biological_processes:
  - preferred_term: SMAD protein signal transduction
    term:
      id: GO:0060395
      label: SMAD protein signal transduction
    modifier: ABNORMAL
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      A 1:1 ratio of mutant-to-wild-type TGFB3 RNA diminished the pSMAD2 and
      pERK1/2 signals to approximately 40% and 60%, respectively, of that
      generated by the w-t TGFB3 RNA alone.
    explanation: >-
      Quantifies the dominant negative reduction of canonical (pSMAD2) and
      non-canonical (pERK1/2) TGF-beta signalling by the index allele in
      Xenopus embryos.
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we confirm a paradoxical up-regulation of both canonical and noncanonical
      TGF-β signaling in association with up-regulation of the expression of
      TGF-β ligands.
    explanation: >-
      Documents the opposite direction of effect in aortic tissue from
      TGFB3-variant patients, supporting the node as "altered" signalling while
      leaving the direction allele- and tissue-dependent.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased pSMAD2 and CTGF expression was observed in the aortic media of
      patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further
      confirming the paradoxical observation of increased TGF‐β signaling in
      vivo
    explanation: >-
      Key reconciling observation: the very same loss-of-function TGFB3 alleles
      produce increased pSMAD2 and CTGF in the aortic media. This argues the
      apparent contradiction between the reduced-signalling and
      increased-signalling models is tissue-compartment-specific rather than a
      simple allele-direction difference.
  downstream:
  - target: Impaired Mesenchymal Development
    description: >-
      Reduced TGF-beta 3 signalling during early mesenchymal development impairs
      myogenesis and palatogenesis.
    hypothesis_groups:
    - reduced_tgfb3_signaling
  - target: Aortic Medial Degeneration and Wall Weakening
    description: >-
      Dysregulated TGF-beta signalling in the aortic wall drives medial
      degeneration in the vascular presentation of the syndrome.
    hypothesis_groups:
    - paradoxical_aortic_tgfb_upregulation
    evidence:
    - reference: PMID:29392890
      reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        increased pSMAD2 and CTGF expression was observed in the aortic media of
        patients with either loss‐of‐function TGFB2 or TGFB3 mutations
      explanation: >-
        Localises the increased TGF-beta signalling specifically to the aortic
        media of TGFB3-variant patients, supporting this causal edge.
- name: Impaired Mesenchymal Development
  biological_scale: CELLULAR
  description: >-
    TGF-beta 3 is the most abundant TGF-beta isoform in developing skeletal
    muscle and is required for the epithelial-to-mesenchymal transition of the
    dermomyotome that generates myogenic precursors, and for confluence of the
    palatal shelves. Insufficient TGFB3 signalling at these stages is proposed
    to reduce the pool of embryonic muscle precursor cells - producing
    hypomyoplasia with normal muscle architecture rather than a myopathy - and
    to prevent complete palatal fusion.
  biological_processes:
  - preferred_term: epithelial to mesenchymal transition
    term:
      id: GO:0001837
      label: epithelial to mesenchymal transition
    modifier: DECREASED
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      Partial or incomplete EMT may diminish the number of embryonic muscle
      precursor cells, ultimately reducing post-natal myofibril mass but not
      affecting muscle architecture.
    explanation: >-
      States the proposed cellular mechanism linking reduced TGFB3 signalling
      to hypomyoplasia with preserved muscle architecture. Downgraded to
      PARTIAL/OTHER because the authors frame this as a hypothesis ("may
      diminish") built on developmental-biology literature rather than an
      observation in their patient; the preserved muscle architecture it
      predicts is separately evidenced by the muscle biopsy.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TGFB3 is essential for both human palatogenesis and normal muscle growth.
    explanation: >-
      Establishes the two mesenchymal developmental programs that require
      TGFB3.
  downstream:
  - target: Hypomyoplasia and Growth Failure
    description: >-
      A reduced embryonic muscle precursor pool yields low post-natal muscle
      mass and impaired somatic growth.
    evidence:
    - reference: PMID:23824657
      reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
      supports: PARTIAL
      evidence_source: OTHER
      snippet: >-
        Thus, a deficiency of TGFB3 during early myogenesis could result in
        hypomyoplasia throughout development that clinically mimics, but is
        etiologically and histologically distinct from, the myopathy caused by
        excess TGF-β signaling found in MFS.
      explanation: >-
        States the proposed causal link from a developmental TGFB3 deficiency to
        hypomyoplasia, and distinguishes it from Marfan myopathy. Downgraded to
        PARTIAL/OTHER because the authors present this as a candidate mechanism
        ("could result in") reasoned from developmental literature rather than
        demonstrated in the patient.
  - target: Palatal and Craniofacial Malformation
    description: >-
      Failure of palatal shelf confluence produces bifid uvula and cleft palate.
    evidence:
    - reference: PMID:23824657
      reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        TGFB3 is essential for palatal confluence
      explanation: >-
        States the causal requirement for TGFB3 in palatal confluence. Tagged
        OTHER because within this publication the sentence is a literature
        assertion citing mouse developmental work (Nawshad and Hay 2003,
        Proetzel 1995); the primary mouse evidence is cited separately on this
        same edge as PMID:7493021.
    - reference: PMID:7493021
      reference_title: "Transforming growth factor-beta 3 is required for secondary palate fusion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        This result demonstrates that TGF-beta 3 affects palatal shelf fusion by
        an intrinsic, primary mechanism rather than by effects secondary to
        craniofacial defects.
      explanation: >-
        Model-organism confirmation that the palatal defect is a direct
        consequence of TGF-beta 3 loss.
- name: Hypomyoplasia and Growth Failure
  biological_scale: ORGANISM
  description: >-
    The muscular phenotype is a developmental deficiency of muscle mass
    (hypomyoplasia) rather than a degenerative myopathy. Muscle biopsy in the
    index patient showed essentially normal fibre size and architecture with no
    dystrophic, inflammatory or fibrotic change, sharply distinguishing it from
    the myopathy of Marfan syndrome. Reduced fetal movement from this deficit is
    the proposed origin of the distal arthrogryposis present at birth.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Distal arthrogryposis indicative of reduced fetal movement suggested an
      inborn error of development affecting muscle mass and other developing
      mesenchymal tissues, including the soft palate.
    explanation: >-
      Links the arthrogryposis to reduced fetal movement caused by the
      developmental muscle deficit.
- name: Palatal and Craniofacial Malformation
  biological_scale: TISSUE
  description: >-
    Failure of complete palatal fusion produces the bifid uvula and cleft palate
    that are among the most consistent findings across the TGFB3 phenotypic
    spectrum, together with hypertelorism and other craniofacial features shared
    with Loeys-Dietz and Shprintzen-Goldberg syndromes.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other systemic features overlap clinically with Loeys-Dietz,
      Shprintzen-Goldberg, and Marfan syndromes, including cleft palate, bifid
      uvula, skeletal overgrowth, cervical spine instability and clubfoot
      deformity.
    explanation: >-
      Documents the craniofacial and skeletal feature set in the TGFB3 cohort.
- name: Aortic Medial Degeneration and Wall Weakening
  biological_scale: TISSUE
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
  description: >-
    In the vascular presentation, dysregulated TGF-beta signalling in the aortic
    wall drives medial degeneration and loss of wall integrity, the shared
    tissue-level lesion of the TGF-beta vasculopathies. Notably, and unlike
    other Loeys-Dietz subtypes, striking aortic or arterial tortuosity is not
    part of the TGFB3 phenotype.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In line with previous observations in aortic wall tissues of patients
      with mutations in effectors of TGF-β signaling (TGFBR1/2, SMAD3, and
      TGFB2), we confirm a paradoxical up-regulation of both canonical and
      noncanonical TGF-β signaling
    explanation: >-
      Places TGFB3-related aortic disease in the same aortic-wall TGF-beta
      dysregulation family as the other Loeys-Dietz genes.
  downstream:
  - target: Progressive Aortic Dilation and Aneurysm
    description: >-
      A weakened media dilates progressively under haemodynamic load.
- name: Progressive Aortic Dilation and Aneurysm
  biological_scale: ORGANISM
  conforms_to: "aortopathy_tgfbeta_dysregulation#Progressive Aortic Dilation and Aneurysm"
  description: >-
    Aneurysmal dilation affects the thoracic and/or abdominal aorta and carries
    a risk of dissection and rupture, making early recognition of TGFB3 carriers
    clinically important.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrate that TGFB3 mutations are associated with significant
      cardiovascular involvement, including thoracic/abdominal aortic aneurysm
      and dissection, and mitral valve disease.
    explanation: >-
      Establishes thoracic and abdominal aortic aneurysm as a core feature of
      TGFB3-related disease.
  downstream:
  - target: Aortic Dissection and Rupture
    description: >-
      Progressive dilation culminates in dissection or rupture.
- name: Aortic Dissection and Rupture
  biological_scale: ORGANISM
  conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Dissection and Rupture"
  description: >-
    Dissection or rupture of the dilated aorta is the principal cause of
    mortality in the vascular presentation of the syndrome, and the reason
    early molecular diagnosis and surveillance matter.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings emphasize the broad clinical variability associated with
      TGFB3 mutations and highlight the importance of early recognition of the
      disease because of high cardiovascular risk.
    explanation: >-
      States the high cardiovascular risk that motivates early recognition.
mechanistic_hypotheses:
- hypothesis_group_id: paradoxical_aortic_tgfb_upregulation
  hypothesis_label: Paradoxical aortic TGF-beta up-regulation (vasculopathy model)
  status: CANONICAL
  description: >-
    In patients with TGFB3-related aortic aneurysm, aortic wall tissue shows
    paradoxical up-regulation of canonical and non-canonical TGF-beta signalling
    together with increased TGF-beta ligand expression, mirroring the pattern in
    TGFBR1/2-, SMAD3- and TGFB2-related disease. Under this model the aortopathy
    arises from excess, not deficient, aortic TGF-beta signalling. This is the
    canonical model for the vascular presentation and is the mechanism shared
    with the `aortopathy_tgfbeta_dysregulation` module.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we confirm a paradoxical up-regulation of both canonical and noncanonical
      TGF-β signaling in association with up-regulation of the expression of
      TGF-β ligands.
    explanation: >-
      Directly documents increased aortic TGF-beta signalling in TGFB3-variant
      patients.
- hypothesis_group_id: reduced_tgfb3_signaling
  hypothesis_label: Reduced TGF-beta 3 signalling (hypomorphic / dominant negative model)
  status: ALTERNATIVE
  description: >-
    In the index patient the TGFB3 p.Cys409Tyr allele encoded a signalling-dead
    ligand that acted as a dominant negative, reducing canonical and
    non-canonical TGF-beta signalling. Under this model the phenotype
    (hypomyoplasia, growth retardation, distal arthrogryposis, bifid uvula, no
    vascular disease) follows from insufficient TGFB3 activity during
    mesenchymal development. Recorded as ALTERNATIVE relative to the aortopathy
    model not because the evidence is weaker - it is direct functional evidence
    - but because it is the minority explanatory model within the Loeys-Dietz
    framing and applies to a different allele class and tissue compartment.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Several lines of evidence indicate the mutation is hypomorphic,
      suggesting that decreased TGFB signaling from a loss of TGFB3 activity is
      likely responsible for the clinical phenotype.
    explanation: >-
      States the reduced-signalling conclusion for the index phenotype - the
      inference neither arm-specific sentence makes on its own. Tagged OTHER
      because it is the authors' synthesis pooling both functional arms rather
      than the report of a single experiment; the two items below cite each arm
      separately so that every experimental item carries one evidence_source.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We conclude that the mutant allele encodes a TGFB3 ligand that is not
      functional.
    explanation: >-
      The cell-based arm: HEK293T-expressed, immunoprecipitated mutant ligand
      applied to a p3TP-Lux TGF-beta reporter generated no transcriptional
      signal, establishing that the p.Cys409Tyr ligand is signalling-dead.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We conclude that in the frog system the mutant TGFB3G1226A allele, when
      co-expressed with w-t TGFB3, has a dominant negative effect on TGF-β
      signaling measured by pSMAD2 and pERK1/2, but does not affect signaling by
      BMP2/4/7 ligands measured by pSMAD1.
    explanation: >-
      The whole-organism arm, and the direct evidence for the dominant-negative
      claim in this hypothesis description: co-expression with wild-type TGFB3
      in Xenopus embryos reduced canonical (pSMAD2) and non-canonical (pERK1/2)
      signalling while leaving BMP/pSMAD1 signalling intact, showing the effect
      is specific to the TGF-beta arm rather than general toxicity.
discussions:
- discussion_id: tgfb3_signaling_direction
  kind: CONTROVERSY
  status: OPEN
  prompt: >-
    How can a single gene, TGFB3, produce both a reduced-signalling phenotype
    with no vascular disease and an aortopathy characterised by paradoxically
    increased TGF-beta signalling - is the difference allele-specific,
    tissue-specific, or both?
  attaches_to:
  - pathophysiology#Altered TGF-beta Signal Transduction
  rationale: >-
    The two anchor papers for this syndrome reach opposite conclusions about the
    direction of the signalling defect. Rienhoff et al. showed a signalling-dead,
    dominant negative p.Cys409Tyr ligand that reduced pSMAD2 and pERK1/2, in a
    patient with normal echocardiograms through age 8 and no aortic disease.
    Bertoli-Avella et al. found paradoxical up-regulation of canonical and
    non-canonical TGF-beta signalling in aortic tissue of TGFB3-variant patients
    with aneurysms and dissections. A third report notes that the codon 300
    (latency-associated peptide domain) variants presumably lead to increased
    TGF-beta signalling and are associated with tall stature, whereas the
    Cys409Tyr loss-of-function allele produced growth retardation - suggesting
    that stature itself may read out the direction of the signalling change.
    Whether allele class, tissue context, or the well-described paradoxical
    aortic response to upstream TGF-beta pathway loss reconciles these findings
    is unresolved, and it directly determines whether TGF-beta-directed therapy
    would be expected to help or harm a given patient. The strongest reconciling
    datum so far is that loss-of-function TGFB3 alleles are themselves
    associated with increased pSMAD2 and CTGF in the aortic media, which points
    to a tissue-compartment-specific rather than an allele-direction
    explanation - but that observation has not been paired with matched
    skeletal-muscle data from the same patients, so it does not close the
    question.
  evidence:
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      increased pSMAD2 and CTGF expression was observed in the aortic media of
      patients with either loss‐of‐function TGFB2 or TGFB3 mutations, further
      confirming the paradoxical observation of increased TGF‐β signaling in
      vivo
    explanation: >-
      Shows that loss-of-function TGFB3 alleles nonetheless raise aortic
      TGF-beta signalling, favouring a tissue-specific over an allele-direction
      resolution of the controversy.
  - reference: PMID:26184463
    reference_title: "Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mutations at codon Arg300 presumably lead to increased TGF-beta
      signalling, suggesting that the short or tall stature seen in patients
      with TGFB3 mutations may result from opposing effects of mutations on
      TGF-beta signalling.
    explanation: >-
      Proposes that opposing directions of signalling change explain the
      opposite growth phenotypes across TGFB3 alleles, framing the controversy.
  proposed_experiments:
  - experiment_id: exp_tgfb3_allele_class_signalling_panel
    name: Allele-class by cell-type signalling panel for TGFB3 variants
    description: >-
      Assay canonical (pSMAD2/3) and non-canonical (pERK1/2) signalling output
      for a panel of TGFB3 alleles - cysteine-knot (p.Cys409Tyr), LAP-domain
      (p.Arg300Gln, p.Arg300Gly) and haploinsufficiency - in matched primary
      aortic smooth muscle cells and skeletal myoblasts derived from patient
      induced pluripotent stem cells, to test whether the direction of effect
      tracks with allele class, with cell type, or with both.
  - experiment_id: exp_tgfb3_genotype_phenotype_stratification
    name: Allele-stratified genotype-phenotype survey of the TGFB3 cohort
    description: >-
      Systematically collect aortic imaging and stature data across the reported
      TGFB3 cohort stratified by allele class, to test the prediction that
      LAP-domain variants associate with tall stature and aortopathy while
      cysteine-knot loss-of-function alleles associate with growth retardation
      and spared vasculature.
- discussion_id: tgfb3_vascular_risk_in_nonvascular_presentation
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What is the lifetime aortic risk for an individual carrying a
    loss-of-function TGFB3 allele who presents with the muscular and skeletal
    phenotype and has normal aortic imaging in childhood?
  attaches_to:
  - pathophysiology#Progressive Aortic Dilation and Aneurysm
  rationale: >-
    The index patient had yearly echocardiograms from 18 months with normal
    aortic root dimensions at 6.5 years, and uncertainty about her vascular risk
    was explicitly named as a principal clinical concern. Because the same gene
    causes aneurysms and dissections in other families, it is not known whether
    childhood-normal imaging in a loss-of-function carrier predicts lifelong
    freedom from aortopathy or merely later onset. This gap has direct
    surveillance consequences for a rare disorder in which no natural-history
    cohort spanning both presentations exists.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The principal clinical concerns for this patient have been growth
      retardation, weakness related to decreased muscle mass and uncertainty
      about her risk for vascular disease.
    explanation: >-
      Names the unresolved vascular risk in the non-vascular presentation as an
      explicit clinical concern.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The full phenotypic spectrum and natural history of TGFB3 mutations must
      await other cases
    explanation: >-
      The authors state explicitly that the natural history is unknown.
  proposed_experiments:
  - experiment_id: exp_tgfb3_natural_history_registry
    name: International TGFB3 natural-history registry with protocolised imaging
    description: >-
      Establish an international TGFB3 registry with protocolised aortic imaging
      (echocardiography plus whole-arterial-tree magnetic resonance or computed
      tomography angiography) and longitudinal follow-up, stratified by allele
      class, to derive age-specific cumulative aortic-event risk for carriers
      who are imaging-normal in childhood.
- discussion_id: lds_wide_features_not_confirmed_for_tgfb3
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Which of the Loeys-Dietz syndrome features catalogued gene-agnostically by
    GeneReviews - cerebral aneurysm, craniosynostosis, strabismus, the cutaneous
    triad of velvety translucent skin, easy bruising and dystrophic scars, and
    the allergic/inflammatory and gastrointestinal predisposition - actually
    occur in TGFB3-related disease?
  attaches_to:
  - pathophysiology#Palatal and Craniofacial Malformation
  rationale: >-
    The only GeneReviews chapter covering this disorder is the gene-agnostic
    Loeys-Dietz syndrome chapter, which pools findings across SMAD2, SMAD3,
    TGFB2, TGFB3, TGFBR1, TGFBR2 and IPO8. The two TGFB3-specific primary
    sources do not report cerebral aneurysm, craniosynostosis or the
    allergic/inflammatory phenotype, and the index patient is explicitly
    described as having skin of normal texture, tension and wound healing -
    a direct contrast with the LDS cutaneous triad. Arterial tortuosity, a
    hallmark of other LDS subtypes, is likewise absent from the TGFB3
    phenotype. This entry therefore curates only features with TGFB3-specific
    evidence and does not import the remaining LDS-wide features, but whether
    their absence reflects genuine gene-specific sparing or merely the small
    published cohort is unresolved. It matters because gene-agnostic LDS
    surveillance protocols (for example cerebrovascular imaging) may be either
    over- or under-inclusive for TGFB3 carriers.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Wide variation in the distribution and severity of clinical features can
      be seen in individuals with LDS, even among affected individuals within a
      family who have the same pathogenic variant.
    explanation: >-
      GeneReviews itself flags that feature distribution varies widely, which is
      why LDS-wide features cannot be assumed to apply to TGFB3 carriers.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her skin had normal texture, tension, and wound healing.
    explanation: >-
      The index patient explicitly lacked the LDS cutaneous findings, supporting
      the decision not to import them into this entry.
  proposed_experiments:
  - experiment_id: exp_tgfb3_gene_specific_feature_audit
    name: Gene-stratified feature audit across the Loeys-Dietz gene panel
    description: >-
      Re-analyse existing multicentre Loeys-Dietz cohorts with per-gene
      stratification and protocolised ascertainment of cerebrovascular imaging,
      dermatological examination, and allergic/gastrointestinal history, to
      determine which LDS features are genuinely shared across all causal genes
      and which are gene-specific. Report TGFB3 carriers separately rather than
      pooled.
- discussion_id: tgfb3_mouse_null_vs_human_heterozygote
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does the homozygous Tgfb3-null mouse, the only well-characterised model for
    this disease, faithfully model a human disorder in which essentially every
    patient is heterozygous and many alleles are hypomorphic or motif-specific
    rather than complete nulls?
  attaches_to:
  - pathophysiology#Impaired Mesenchymal Development
  - pathophysiology#Palatal and Craniofacial Malformation
  rationale: >-
    The dose mismatch is the core issue: the mouse evidence for the palatal
    mechanism comes from biallelic nulls, whereas human Rienhoff syndrome is
    autosomal dominant and heterozygous. Human alleles are also mechanistically
    varied (cysteine-knot disruption, RKKR furin-cleavage-motif disruption,
    latency-associated peptide domain substitutions), so a complete null is not
    an obvious surrogate for any of them. The direction of effect diverges too:
    the mouse null is a pure loss of ligand, while human loss-of-function
    alleles are associated with increased pSMAD2 in the aortic media. The mouse
    is nonetheless the strongest available support for the palatogenesis
    mechanism, and the congenic-background series offers a real mechanistic
    parallel to human reduced penetrance - so this is a translational-validity
    caveat on an otherwise well-evidenced node, not an absence of evidence.
  evidence:
  - reference: PMID:7493021
    reference_title: "Transforming growth factor-beta 3 is required for secondary palate fusion."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice lacking TGF-beta 3 exhibit an incompletely penetrant failure of the
      palatal shelves to fuse leading to cleft palate.
    explanation: >-
      The supporting palatal evidence comes from complete-null mice, not from a
      heterozygous model matching the human genotype.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A second de novo mutation was found in TGFB3 (c.1226G>A; pC409Y).
    explanation: >-
      Confirms the human disease genotype is a heterozygous missense allele, not
      the biallelic null modelled in mouse.
  proposed_experiments:
  - experiment_id: exp_tgfb3_heterozygous_knockin_mouse
    name: Allele-matched heterozygous Tgfb3 knock-in mouse series
    description: >-
      Generate heterozygous mouse lines carrying the orthologous human alleles
      (cysteine-knot p.Cys409Tyr, an RKKR-motif variant, and a
      latency-associated peptide domain variant) rather than a null, and
      phenotype palate, skeletal muscle mass and aortic wall in parallel.
      Compare each line's SMAD2 phosphorylation in palate, muscle and aorta to
      test whether one genotype can reproduce both the muscular and the
      vascular arms of the human disease.
differential_diagnoses:
- name: Marfan syndrome
  disease_term:
    preferred_term: Marfan syndrome
    term:
      id: MONDO:0007947
      label: Marfan syndrome
  description: >-
    Shares aortic aneurysm, arachnodactyly, pectus deformity, pes planus, joint
    hyperextensibility and low muscle mass. The index Rienhoff patient was
    explicitly evaluated against and did not meet Marfan diagnostic criteria.
  distinguishing_features:
  - >-
    Marfan syndrome is caused by FBN1 variants and features ectopia lentis,
    which is not part of the TGFB3 phenotype.
  - >-
    Bifid uvula and cleft palate point away from Marfan and toward the
    Loeys-Dietz spectrum.
  - >-
    The muscle histopathology differs decisively: Marfan myopathy shows
    endomysial thickening, fat deposition, split fibres and fibrosis, whereas
    TGFB3-related hypomyoplasia shows essentially normal fibre size and
    architecture.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proposita did not meet the diagnostic criteria established for MFS,
      BHS or LDS.
    explanation: >-
      Documents that the index patient was assessed against, and failed to meet,
      Marfan, Beals-Hecht and Loeys-Dietz criteria.
- name: Loeys-Dietz syndrome (other genetic subtypes)
  disease_term:
    preferred_term: Loeys-Dietz syndrome
    term:
      id: MONDO:0018954
      label: Loeys-Dietz syndrome
  description: >-
    The TGFBR1-, TGFBR2-, SMAD2-, SMAD3-, TGFB2- and IPO8-related subtypes share
    hypertelorism, bifid uvula/cleft palate, skeletal features and aortic
    aneurysm, and are distinguished only by molecular testing.
  distinguishing_features:
  - >-
    Striking aortic and arterial tortuosity, characteristic of the other
    Loeys-Dietz subtypes, is not present in TGFB3-related disease.
  - >-
    TGFB3-related disease uniquely encompasses a non-vascular pole with
    hypomyoplasia and distal arthrogryposis.
  - >-
    Definitive discrimination requires identification of the causal gene.
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      by the identification of a heterozygous pathogenic variant in SMAD2,
      SMAD3, TGFB2, TGFB3, TGFBR1, or TGFBR2
    explanation: >-
      Molecular testing across the Loeys-Dietz gene panel is what discriminates
      the subtypes, since their clinical features overlap.
- name: Beals-Hecht syndrome (congenital contractural arachnodactyly)
  disease_term:
    preferred_term: congenital contractural arachnodactyly
    term:
      id: MONDO:0007363
      label: congenital contractural arachnodactyly
  description: >-
    Shares congenital contractures, arachnodactyly and low muscle mass with the
    non-vascular presentation of Rienhoff syndrome, and was formally considered
    in the differential for the index patient.
  distinguishing_features:
  - >-
    Beals-Hecht syndrome is caused by FBN2 variants and characteristically
    includes crumpled ears; the index Rienhoff patient had normally placed,
    well-formed ears and did not meet Beals-Hecht criteria.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proband shared the clinical feature of low muscle mass with hypotonia
      with three related conditions: Marfan, Loeys–Dietz, and Beals–Hecht
      syndrome (BHS, OMIM # 121050).
    explanation: >-
      Names Beals-Hecht syndrome as a formal differential for the index
      presentation.
- name: Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1)
  disease_term:
    preferred_term: arrhythmogenic right ventricular dysplasia 1
    term:
      id: MONDO:0007152
      label: arrhythmogenic right ventricular dysplasia 1
  description: >-
    A mechanistically and clinically distinct disease caused by variants in the
    same gene. ARVD1 arises from TGFB3 *regulatory* variants in the untranslated
    regions that increase TGFB3 expression, and manifests as fibrofatty
    replacement of right ventricular myocardium with arrhythmia and sudden-death
    risk - not as a connective tissue or aortic disorder. Included here as a
    curation guard: TGFB3 gene-disease assertions must be attributed to the
    correct entity, since a coding-region variant implies Rienhoff syndrome
    while a regulatory-region variant implies ARVD1.
  distinguishing_features:
  - >-
    ARVD1 is caused by regulatory (untranslated-region) TGFB3 variants that
    increase promoter/UTR activity, whereas Rienhoff syndrome is caused by
    coding-region variants altering the ligand itself.
  - >-
    ARVD1 presents with right ventricular fibrofatty replacement, ventricular
    arrhythmia and sudden death, without the craniofacial, skeletal or
    aortic-aneurysm features of Rienhoff syndrome.
  evidence:
  - reference: PMID:15639475
    reference_title: "Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified TGFbeta3 as the disease gene involved in ARVD1.
    explanation: >-
      Establishes TGFB3 as the ARVD1 gene, a separate disease entity from
      Rienhoff syndrome despite the shared locus.
  - reference: PMID:15639475
    reference_title: "Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      In vitro expression assays with constructs containing the mutations
      showed that mutated UTRs were twofold more active than wild-types.
    explanation: >-
      Shows the ARVD1 mechanism is increased expression driven by regulatory
      variants, distinct from the coding-variant ligand defect of Rienhoff
      syndrome.
- name: Shprintzen-Goldberg syndrome
  disease_term:
    preferred_term: Shprintzen-Goldberg syndrome
    term:
      id: MONDO:0008426
      label: Shprintzen-Goldberg syndrome
  description: >-
    A marfanoid craniosynostosis syndrome whose systemic features overlap those
    of TGFB3-related disease, explicitly named in the TGFB3 cohort report.
  distinguishing_features:
  - >-
    Shprintzen-Goldberg syndrome is caused by SKI variants and characteristically
    includes craniosynostosis and intellectual disability, neither of which is
    documented in TGFB3-related disease; the index Rienhoff patient had
    age-appropriate neurocognitive development.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other systemic features overlap clinically with Loeys-Dietz,
      Shprintzen-Goldberg, and Marfan syndromes
    explanation: >-
      Names Shprintzen-Goldberg syndrome among the syndromes whose systemic
      features overlap TGFB3-related disease.
phenotypes:
- name: Thoracic Aortic Aneurysm
  category: Cardiovascular
  description: >-
    Aneurysmal dilation of the thoracic aorta, with risk of dissection and
    rupture, is the principal cardiovascular manifestation in the vascular
    presentation of the syndrome.
  phenotype_term:
    preferred_term: Thoracic aortic aneurysm
    term:
      id: HP:0012727
      label: Thoracic aortic aneurysm
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrate that TGFB3 mutations are associated with significant
      cardiovascular involvement, including thoracic/abdominal aortic aneurysm
      and dissection, and mitral valve disease.
    explanation: >-
      Documents thoracic aortic aneurysm in the 43-patient TGFB3 cohort.
- name: Abdominal Aortic Aneurysm
  category: Cardiovascular
  description: >-
    Involvement of the abdominal aorta distinguishes TGFB3-related disease from
    aortopathies confined to the aortic root.
  phenotype_term:
    preferred_term: Abdominal aortic aneurysm
    term:
      id: HP:0005112
      label: Abdominal aortic aneurysm
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including thoracic/abdominal aortic aneurysm and dissection
    explanation: >-
      Explicitly includes abdominal aortic aneurysm in the TGFB3 phenotype.
- name: Aortic Dissection
  category: Cardiovascular
  description: >-
    Dissection of the aorta, the principal life-threatening complication of the
    vascular presentation.
  phenotype_term:
    preferred_term: Aortic dissection
    term:
      id: HP:0002647
      label: Aortic dissection
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including thoracic/abdominal aortic aneurysm and dissection
    explanation: >-
      Documents aortic dissection as part of the TGFB3 cardiovascular
      phenotype.
- name: Aortic Root Dilatation
  category: Cardiovascular
  description: >-
    Dilatation of the aortic root, reported in 29% of the largest published
    TGFB3 cohort - a lower rate than in TGFBR1/2-related Loeys-Dietz syndrome,
    consistent with the milder cardiovascular phenotype of this subtype.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aortic root dilatation and mitral valve disease represented the most
      common cardiovascular findings, reported in 29% and 32% of patients,
      respectively.
    explanation: >-
      Quantifies aortic root dilatation at 29% in a 32-patient TGFB3 cohort,
      mapping to OCCASIONAL (5-29%).
- name: Mitral Valve Disease
  category: Cardiovascular
  description: >-
    Mitral valve abnormality is a recognised cardiac feature alongside the
    aortopathy, and at 32% is the most common cardiovascular finding in the
    largest published TGFB3 cohort.
  phenotype_term:
    preferred_term: Abnormal mitral valve morphology
    term:
      id: HP:0001633
      label: Abnormal mitral valve morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aortic root dilatation and mitral valve disease represented the most
      common cardiovascular findings, reported in 29% and 32% of patients,
      respectively.
    explanation: >-
      Quantifies mitral valve disease at 32% in the TGFB3 cohort, mapping to
      FREQUENT (30-79%).
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      significant cardiovascular involvement, including thoracic/abdominal
      aortic aneurysm and dissection, and mitral valve disease
    explanation: >-
      Lists mitral valve disease among the significant cardiovascular
      manifestations of TGFB3 variants.
- name: Bifid Uvula
  category: Craniofacial
  description: >-
    A bifid uvula, reflecting incomplete midline palatal fusion, is among the
    most consistent findings across the whole TGFB3 phenotypic spectrum,
    present both in the index non-vascular case and in the aortopathy cohort.
  phenotype_term:
    preferred_term: Bifid uvula
    term:
      id: HP:0000193
      label: Bifid uvula
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a syndrome presenting at birth with distal arthrogryposis,
      hypotonia, bifid uvula, a failure of normal post-natal muscle development
      without evidence of vascular disease
    explanation: >-
      Bifid uvula was present at birth in the index patient.
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including cleft palate, bifid uvula, skeletal overgrowth, cervical spine
      instability and clubfoot deformity
    explanation: >-
      Bifid uvula recurs in the independent TGFB3 aortopathy cohort.
- name: Cleft Palate
  category: Craniofacial
  description: >-
    Failure of complete palatal shelf confluence produces overt cleft palate in
    a subset of patients; TGFB3 is essential for human palatogenesis.
  phenotype_term:
    preferred_term: Cleft palate
    term:
      id: HP:0000175
      label: Cleft palate
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including cleft palate, bifid uvula, skeletal overgrowth, cervical spine
      instability and clubfoot deformity
    explanation: >-
      Documents cleft palate in the TGFB3 cohort.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TGFB3 is essential for both human palatogenesis and normal muscle growth.
    explanation: >-
      Establishes the causal requirement for TGFB3 in palatogenesis underlying
      the palatal phenotype.
- name: Hypertelorism
  category: Craniofacial
  description: >-
    Increased interocular distance, one of the two non-vascular findings that
    classically define Loeys-Dietz syndrome, was present in the index patient.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She was hyperteloric and had a bifid uvula, the two non-vascular findings
      that define LDS
    explanation: >-
      Documents hypertelorism in the index patient.
- name: Retrognathia
  category: Craniofacial
  description: >-
    Posterior positioning of the mandible, noted repeatedly across the index
    patient's serial examinations.
  phenotype_term:
    preferred_term: Retrognathia
    term:
      id: HP:0000278
      label: Retrognathia
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also noted was bilateral pes planus, mild pectus excavatum,
      hyperextensibility of multiple large joints, and mild retrognathia.
    explanation: >-
      Documents retrognathia in the index patient.
- name: Distal Arthrogryposis
  category: Musculoskeletal
  description: >-
    Congenital contractures of the distal joints, most severe in the fingers and
    toes, present at birth and attributed to reduced fetal movement from the
    developmental muscle deficit.
  phenotype_term:
    preferred_term: Distal arthrogryposis
    term:
      id: HP:0005684
      label: Distal arthrogryposis
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a syndrome presenting at birth with distal arthrogryposis,
      hypotonia, bifid uvula, a failure of normal post-natal muscle development
      without evidence of vascular disease
    explanation: >-
      Distal arthrogryposis was present at birth in the index patient.
- name: Decreased Muscle Mass
  category: Musculoskeletal
  description: >-
    A developmental deficiency of muscle bulk (hypomyoplasia) affecting
    appendicular and axial muscles, with preserved fibre architecture on biopsy,
    distinguishing it from the myopathy of Marfan syndrome.
  phenotype_term:
    preferred_term: Decreased muscle mass
    term:
      id: HP:0003199
      label: Decreased muscle mass
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her motor examination revealed decreased bulk in all appendicular and
      axial muscles, strength 1/5, low tone, and diminished reflexes
      throughout.
    explanation: >-
      Direct clinical documentation of reduced muscle bulk and weakness in the
      index patient.
  - reference: PMID:32022420
    reference_title: "Homozygous deletion of exons 2-7 within TGFB3 gene in a child with severe Loeys-Dietz syndrome and Marfan-like features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      musculoskeletal abnormalities-severe scoliosis, joint laxity, long
      digits, flat feet, decreased muscle mass, and diminished muscle strength
    explanation: >-
      Independent corroboration of decreased muscle mass and strength in a
      second, unrelated TGFB3 patient (homozygous exon 2-7 deletion), which
      matters because the muscular phenotype was otherwise supported only by
      the single index case.
- name: Scoliosis
  category: Musculoskeletal
  description: >-
    Lateral curvature of the spine. Scoliosis is part of the Loeys-Dietz
    skeletal spectrum generally, and severe scoliosis was documented in a
    TGFB3 patient with a homozygous exon 2-7 deletion. It is not separately
    quantified in the heterozygous cohort, so no frequency is asserted.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:32022420
    reference_title: "Homozygous deletion of exons 2-7 within TGFB3 gene in a child with severe Loeys-Dietz syndrome and Marfan-like features."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      musculoskeletal abnormalities-severe scoliosis, joint laxity, long
      digits, flat feet, decreased muscle mass, and diminished muscle strength
    explanation: >-
      Documents severe scoliosis in a TGFB3 patient, though in the more severely
      affected homozygous state rather than the typical heterozygous
      presentation.
- name: Cervical Spine Instability
  category: Musculoskeletal
  description: >-
    Instability of the cervical spine, a feature shared with other Loeys-Dietz
    subtypes and relevant to anaesthetic and perioperative management.
  phenotype_term:
    preferred_term: Cervical instability
    term:
      id: HP:0008462
      label: Cervical instability
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including cleft palate, bifid uvula, skeletal overgrowth, cervical spine
      instability and clubfoot deformity
    explanation: >-
      Documents cervical spine instability in the TGFB3 cohort.
- name: Talipes Equinovarus
  category: Musculoskeletal
  description: >-
    Clubfoot deformity is part of the skeletal feature set in the TGFB3
    aortopathy cohort.
  phenotype_term:
    preferred_term: Talipes equinovarus
    term:
      id: HP:0001762
      label: Talipes equinovarus
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      including cleft palate, bifid uvula, skeletal overgrowth, cervical spine
      instability and clubfoot deformity
    explanation: >-
      Documents clubfoot deformity in the TGFB3 cohort.
- name: High Palate
  category: Craniofacial
  description: >-
    A high-arched palate is the single most frequent systemic feature in the
    largest published TGFB3 cohort, present in 65% of patients.
  phenotype_term:
    preferred_term: High palate
    term:
      id: HP:0000218
      label: High palate
  frequency: FREQUENT
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A high frequency of systemic features (65% high-arched palate, 63%
      arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was
      observed.
    explanation: >-
      Quantifies high-arched palate at 65% in a 32-patient, 17-family TGFB3
      cohort, mapping to FREQUENT (30-79%).
- name: Arachnodactyly
  category: Musculoskeletal
  description: >-
    Long slender digits, one of the Marfanoid skeletal features seen across the
    TGFB3 spectrum, present in 63% of the largest published cohort.
  phenotype_term:
    preferred_term: Arachnodactyly
    term:
      id: HP:0001166
      label: Arachnodactyly
  frequency: FREQUENT
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A high frequency of systemic features (65% high-arched palate, 63%
      arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was
      observed.
    explanation: >-
      Quantifies arachnodactyly at 63% in the TGFB3 cohort, mapping to FREQUENT
      (30-79%).
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the skeletal findings typical of MFS included arachnodactyly, pectus
      excavatum, pes planus, and hyperextensible large joints
    explanation: >-
      Documents arachnodactyly among the Marfanoid skeletal findings in the
      index patient.
  - reference: PMID:26184463
    reference_title: "Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      had tall stature, arachnodactyly, hyperextensible joints, hypertelorism,
      bifid uvula
    explanation: >-
      Arachnodactyly recurs in an independent TGFB3 family.
- name: Joint Hypermobility
  category: Musculoskeletal
  description: >-
    Hyperextensibility of multiple large joints, notably elbows and knees, is
    present across TGFB3 families and was documented in 52% of the largest
    published cohort.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  frequency: FREQUENT
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A high frequency of systemic features (65% high-arched palate, 63%
      arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was
      observed.
    explanation: >-
      Quantifies joint hypermobility at 52% in the TGFB3 cohort, mapping to
      FREQUENT (30-79%).
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The skin had normal texture, subcutaneous fat was minimal, and marked
      hyperextensibility was present in elbows and knees.
    explanation: >-
      Documents marked large-joint hyperextensibility in the index patient.
- name: Pectus Deformity
  category: Musculoskeletal
  description: >-
    Anterior chest wall (sternal) deformity, reported in 57% of the largest
    published TGFB3 cohort without separation into excavatum and carinatum
    subtypes; bound to the generic sternal-morphology term for that reason.
  phenotype_term:
    preferred_term: Abnormal sternum morphology
    term:
      id: HP:0000766
      label: Abnormal sternum morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A high frequency of systemic features (65% high-arched palate, 63%
      arachnodactyly, 57% pectus deformity, 52% joint hypermobility) was
      observed.
    explanation: >-
      Quantifies pectus deformity at 57% in the TGFB3 cohort, mapping to
      FREQUENT (30-79%). The cohort reports "pectus deformity" without
      specifying excavatum versus carinatum, so the generic sternal term is
      used here.
- name: Pectus Excavatum
  category: Musculoskeletal
  description: >-
    Anterior chest wall deformity, one of the Marfanoid skeletal features of the
    syndrome; the specific excavatum subtype was documented in the index
    patient.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the skeletal findings typical of MFS included arachnodactyly, pectus
      excavatum, pes planus, and hyperextensible large joints
    explanation: >-
      Documents pectus excavatum in the index patient.
- name: Pes Planus
  category: Musculoskeletal
  description: >-
    Flat feet, part of the Marfanoid skeletal feature set.
  phenotype_term:
    preferred_term: Pes planus
    term:
      id: HP:0001763
      label: Pes planus
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Also noted was bilateral pes planus, mild pectus excavatum,
      hyperextensibility of multiple large joints, and mild retrognathia.
    explanation: >-
      Documents bilateral pes planus in the index patient.
- name: Growth Delay
  category: Growth
  description: >-
    Marked postnatal growth failure, with weight persistently below the 1st
    centile in the index patient, was one of the principal clinical concerns.
    Growth direction appears allele-dependent: the cysteine-knot
    loss-of-function allele produced growth retardation, whereas codon-300
    variants have been associated with overgrowth and tall stature.
  phenotype_term:
    preferred_term: Growth delay
    term:
      id: HP:0001510
      label: Growth delay
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At age 3 months, the patient was evaluated for failure-to-thrive because
      of low weight (4.2 kg <5th centile) and a delay in gross motor function.
    explanation: >-
      Documents early growth failure in the index patient.
- name: Tall Stature
  category: Growth
  description: >-
    At the opposite pole of the phenotypic spectrum, skeletal overgrowth and
    tall stature occur in patients with codon-300 latency-associated peptide
    domain variants and in the aortopathy cohort.
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: PMID:26184463
    reference_title: "Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The two affected children and their affected father had tall stature,
      arachnodactyly, hyperextensible joints, hypertelorism, bifid uvula, but
      no cardiac involvement
    explanation: >-
      Documents tall stature in a three-generation family with the TGFB3
      p.Arg300Gly variant.
- name: Hypotonia
  category: Neurological
  description: >-
    Low muscle tone was noted from birth and persisted, accompanying the reduced
    muscle bulk and diminished reflexes.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was a midline facial nevus flammeus and mild hypotonia.
    explanation: >-
      Hypotonia documented on the newborn physical examination.
- name: Motor Delay
  category: Neurological
  description: >-
    Gross motor milestones were markedly delayed as a consequence of the muscle
    deficit; the index patient walked at 24 months with a waddling gait and a
    positive Gower sign, while neurocognitive development was normal.
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      An evaluation at 17 months showed that she did not crawl or roll, but
      could stand with support.
    explanation: >-
      Direct documentation of markedly delayed gross motor milestones in the
      index patient.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Her neurocognitive development was appropriate for age.
    explanation: >-
      Confirms the delay was motor rather than cognitive, consistent with a
      primary muscle deficit rather than a neurodevelopmental disorder.
- name: Blue Sclerae
  category: Ophthalmologic
  description: >-
    Blue sclerae, a connective tissue sign, were documented in the index
    patient.
  phenotype_term:
    preferred_term: Blue sclerae
    term:
      id: HP:0000592
      label: Blue sclerae
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The sclerae were blue.
    explanation: >-
      Direct documentation of blue sclerae on examination.
histopathology:
- name: Hypomyoplasia with Preserved Muscle Architecture
  description: >-
    Quadriceps muscle biopsy in the index patient showed a normal checkerboard
    pattern with type 1 fibre predominance and only mild, focal type 1 fibre
    disproportion consistent with disuse. Critically, there was no endomysial
    thickening, fat deposition, fibre splitting or fibrosis - the changes that
    characterise the myopathy of Marfan syndrome - establishing the muscle
    lesion as a developmental deficiency of muscle mass rather than a
    degenerative myopathy.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A muscle biopsy showed essentially normal fiber size and architecture.
      There was no evidence of chronic dystrophic or inflammatory changes
      presenting a strikingly different histologic picture compared to the
      myopathic findings in congenital or classical MFS
    explanation: >-
      Direct human muscle histology distinguishing TGFB3-related hypomyoplasia
      from Marfan myopathy.
  notes: >-
    No finding_term is bound because the HistopathologyFindingTerm dynamic enum
    is reachable only from selected NCIT branches plus HP:0025461, and neither
    NCIT nor that HPO branch offers a term for developmental hypomyoplasia with
    preserved architecture.
genetic:
- name: TGFB3
  gene_term:
    preferred_term: TGFB3
    term:
      id: hgnc:11769
      label: TGFB3
  association: Causative
  relationship_type: CAUSATIVE
  notes: >-
    Heterozygous variants in TGFB3, encoding the transforming growth factor beta
    3 ligand, cause Rienhoff syndrome (Loeys-Dietz syndrome type 5). Reported
    alleles fall into at least two mechanistic classes. The index de novo
    c.1226G>A (p.Cys409Tyr) variant lies in the last exon and destroys the
    cysteine knot of the mature ligand, producing a signalling-dead protein that
    acts as a dominant negative. A second class of variants affects codon 300 of
    the latency-associated peptide domain (p.Arg300Gln, p.Arg300Gly) and is
    proposed to increase TGF-beta signalling; these have been associated with
    overgrowth and tall stature rather than growth retardation. Additional
    variants were identified across 11 families with syndromic aortic aneurysms.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A second de novo mutation was found in TGFB3 (c.1226G>A; pC409Y).
      Validation by Sanger sequencing confirmed that this mutation was de novo
      in the proband.
    explanation: >-
      Identifies and validates the causal de novo TGFB3 variant in the index
      patient.
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report on 43 patients from 11 families with syndromic
      presentations of aortic aneurysms caused by TGFB3 mutations.
    explanation: >-
      Establishes TGFB3 as a cause of syndromic aortic aneurysm across multiple
      independent families.
  - reference: PMID:26184463
    reference_title: "Exome sequencing identifies a novel heterozygous TGFB3 mutation in a disorder overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We detected a novel heterozygous mutation in TGFB3, c.898C>G, predicting
      the missense substitution p.Arg300Gly. Sanger sequencing confirmed the
      mutation and its segregation with the phenotype.
    explanation: >-
      Documents a second allele class with familial segregation, supporting
      autosomal dominant TGFB3-related disease.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The majority of the TGFB3 mutations consist of missense mutations (60%),
      whereas 20% are frameshift mutations, 13% are nonsense mutations, and 7%
      of mutations affect a splice site.
    explanation: >-
      Quantifies the TGFB3 variant-class distribution across the reported
      mutation set.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For TGFB3, 35% of mutations affect the RKKR‐motif.
    explanation: >-
      Identifies the RKKR furin-cleavage motif - required to release the mature
      ligand from the latency-associated peptide - as the principal mutational
      hotspot in TGFB3.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Remarkably, of the 23 currently known TGFB3 mutations, three substitute
      histidine for aspartic acid at amino acid position 263.
    explanation: >-
      Documents a recurrent p.Asp263His substitution accounting for three of 23
      reported TGFB3 mutations, raising a possible founder effect.
  - reference: ORPHA:60030
    reference_title: "Loeys-Dietz syndrome (Orphanet)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TGFB3 | transforming growth factor beta 3 | hgnc:11769 | Disease-causing germline mutation(s) in"
    explanation: >-
      Orphanet curates TGFB3 as a disease-causing gene within the Loeys-Dietz
      syndrome group.
animal_models:
- species: Mouse (Mus musculus)
  genotype: Homozygous Tgfb3 null (Tgfb3-/-)
  category: Knockout
  genes:
  - preferred_term: Tgfb3
    term:
      id: hgnc:11769
      label: TGFB3
  associated_phenotypes:
  - Cleft palate
  - Failure of palatal shelf fusion
  description: >-
    The Tgfb3-null mouse is the primary model for the palatal arm of the
    syndrome. It shows an incompletely penetrant failure of palatal shelf
    fusion producing cleft palate, caused by impaired adhesion of the apposing
    medial edge epithelia and failure to eliminate the mid-line epithelial
    seam. Critically, no other craniofacial abnormalities accompany it,
    establishing that TGF-beta 3 acts on palatal fusion by an intrinsic,
    primary mechanism rather than secondarily to a craniofacial malformation -
    the model-organism support for the "Palatal and Craniofacial Malformation"
    node. Note the model is a complete biallelic null, whereas human patients
    are heterozygous; see discussion `tgfb3_mouse_null_vs_human_heterozygote`.
  evidence:
  - reference: PMID:7493021
    reference_title: "Transforming growth factor-beta 3 is required for secondary palate fusion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice lacking TGF-beta 3 exhibit an incompletely penetrant failure of the
      palatal shelves to fuse leading to cleft palate. The defect appears to
      result from impaired adhesion of the apposing medial edge epithelia of
      the palatal shelves and subsequent elimination of the mid-line epithelial
      seam.
    explanation: >-
      Establishes the cellular mechanism by which TGF-beta 3 loss causes failed
      palatal fusion.
  - reference: PMID:7493021
    reference_title: "Transforming growth factor-beta 3 is required for secondary palate fusion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      No craniofacial abnormalities were observed. This result demonstrates
      that TGF-beta 3 affects palatal shelf fusion by an intrinsic, primary
      mechanism rather than by effects secondary to craniofacial defects.
    explanation: >-
      Shows the palatal defect is primary rather than a downstream consequence
      of craniofacial malformation.
- species: Mouse (Mus musculus)
  genotype: Tgfb3 knockout congenic strains on five genetic backgrounds
  category: Knockout
  background: Five different congenic genetic backgrounds
  genes:
  - preferred_term: Tgfb3
    term:
      id: hgnc:11769
      label: TGFB3
  associated_phenotypes:
  - Cleft palate
  description: >-
    Congenic Tgfb3-knockout strains carrying the identical defective Tgfb3
    allele on five different genetic backgrounds show different cleft palate
    phenotypes, tracking with each strain's capacity to disintegrate the medial
    edge epithelium and basement membrane. This is a mechanistic model-organism
    parallel for the reduced and variable penetrance observed in human TGFB3
    families, though it does not by itself identify a human modifier locus.
  evidence:
  - reference: PMID:32603777
    reference_title: "Genetic background influences the capacity for medial edge epithelium disintegration and phenotype of cleft palate in TGFβ3 knockout mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Although the five congenic strains carried the same defective Tgfb3
      gene, the fetal palate phenotypes differed among strains.
    explanation: >-
      Demonstrates genetic-background modulation of the Tgfb3-null phenotype,
      a candidate explanation for variable expressivity in human carriers.
progression:
- phase: Prenatal and neonatal
  age_range: Birth
  notes: >-
    In the muscular presentation, the disorder is manifest at birth with distal
    contractures, hypotonia and bifid uvula, reflecting a developmental process
    already complete in utero.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We describe a syndrome presenting at birth with distal arthrogryposis,
      hypotonia, bifid uvula
    explanation: >-
      Establishes presentation at birth in the muscular phenotype.
- phase: Infancy and childhood
  age_range: Infancy to childhood
  notes: >-
    Growth failure and gross motor delay dominate childhood in the muscular
    presentation. In the index patient, yearly echocardiograms from 18 months
    and aortic measurements at 6.5 years remained normal, and digit contractures
    persisted but hand function was good by age 9.
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yearly echocardiograms beginning at 18 months showed no cardiac defect or
      dysfunction.
    explanation: >-
      Documents the absence of cardiac involvement through childhood in the
      index patient.
- phase: Adulthood
  age_range: Adulthood
  notes: >-
    In the vascular presentation, aortic aneurysms progress with age and carry a
    high risk of dissection, motivating early molecular recognition and lifelong
    arterial surveillance.
  evidence:
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      highlight the importance of early recognition of the disease because of
      high cardiovascular risk
    explanation: >-
      Supports progressive, high-risk cardiovascular disease as the adult course
      of the vascular presentation.
  - reference: PMID:29392890
    reference_title: "A mutation update on the LDS-associated genes TGFB2/3 and SMAD2/3."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The aortic phenotype in patients with SMAD3 mutations is very similar to
      TGFBR1/2 patients, whereas TGFB2 and TGFB3 cardiovascular features tend
      to be milder, although severe aortic presentation at young age has also
      been observed.
    explanation: >-
      Qualifies the adult vascular course: TGFB3 cardiovascular disease tends to
      be milder than TGFBR1/2- or SMAD3-related Loeys-Dietz syndrome, but the
      milder average does not exclude severe early presentations, so
      surveillance is not relaxed on genotype alone.
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dissection involving distal aortic segments occurred in two patients at
      age 50 and 52 years.
    explanation: >-
      Dates the observed dissections to the sixth decade and localises them to
      distal aortic segments - later and more distal than the classic
      Loeys-Dietz pattern of early proximal dissection, and the reason
      surveillance must cover the whole aorta rather than the root alone.
treatments:
- name: Arterial-Tree Imaging Surveillance
  description: >-
    Serial echocardiography of the aortic root and ascending aorta together with
    magnetic resonance or computed tomography angiography of the entire arterial
    tree. Because TGFB3-related disease involves the abdominal as well as the
    thoracic aorta, surveillance cannot be confined to the aortic root.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Echocardiography to monitor the status of the aortic root and ascending
      aorta (at least annually) and magnetic resonance angiography or
      computerized tomography angiography to assess the entire arterial tree
    explanation: >-
      GeneReviews specifies the whole-arterial-tree surveillance regimen for
      Loeys-Dietz syndrome, which includes TGFB3-related LDS type 5.
- name: Beta-Adrenergic Blocker Therapy
  description: >-
    Beta-adrenergic receptor blockers reduce haemodynamic stress on the aortic
    wall with the aim of slowing aneurysm progression.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: beta-adrenergic antagonist
      term:
        id: NCIT:C29576
        label: Beta-Adrenergic Antagonist
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or
      other medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews documents beta-adrenergic receptor blockade to reduce
      haemodynamic stress in Loeys-Dietz syndrome.
- name: Angiotensin Receptor Blocker Therapy
  description: >-
    Angiotensin receptor blockers such as losartan are used to reduce
    haemodynamic stress in Loeys-Dietz syndrome. Their role in Rienhoff syndrome
    is uncertain and direction-dependent: a three-year trial of losartan in the
    index patient produced no change in muscle strength or mass, consistent with
    a pathophysiology of reduced rather than excess TGF-beta signalling in that
    allele class.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: losartan
      term:
        id: CHEBI:6541
        label: losartan
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      angiotensin receptor blockers, beta-adrenergic receptor blockers, or
      other medications are used to reduce hemodynamic stress
    explanation: >-
      GeneReviews documents angiotensin receptor blockade for haemodynamic
      stress reduction in Loeys-Dietz syndrome.
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At age 3 years, a 3-year trial of losartan at a dose of up to 2.0
      mg/kg/day produced no change in muscle strength or mass
    explanation: >-
      A prolonged losartan trial failed to improve the muscular phenotype in the
      index patient, arguing against TGF-beta blockade for the
      reduced-signalling presentation.
  notes: >-
    The muscular phenotype and the aortopathy may require opposite therapeutic
    logic; see discussion `tgfb3_signaling_direction`. Angiotensin receptor
    blockers are contraindicated in pregnancy.
- name: Prophylactic Aortic Surgery
  description: >-
    Aneurysms are amenable to early and aggressive surgical repair; prophylactic
    intervention at appropriate thresholds prevents dissection and rupture.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aneurysms are amenable to early and aggressive surgical intervention
    explanation: >-
      GeneReviews documents early aggressive surgical repair of aneurysms in
      Loeys-Dietz syndrome.
- name: Physical and Occupational Therapy
  description: >-
    Physical and occupational therapy with orthotic support addresses the
    contractures, hypotonia and motor delay of the muscular presentation. The
    index patient received both from six months of age and wore foot orthoses
    from age two, retaining functional hand use despite persistent digit
    contractures.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: physical therapy
    term:
      id: NCIT:C15302
      label: Physical Therapy
  evidence:
  - reference: PMID:23824657
    reference_title: "A mutation in TGFB3 associated with a syndrome of low muscle mass, growth retardation, distal arthrogryposis and clinical features overlapping with Marfan and Loeys-Dietz syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The proband had physical and occupational therapy since the age 6 months,
      and has worn orthotic foot appliances since age 2. Although digit
      contractures persist, at age 9 she has very functional hands.
    explanation: >-
      Documents the rehabilitative management and its functional outcome in the
      index patient.
- name: Activity Restriction and Avoidance of Cardiovascular Stimulants
  description: >-
    Individuals with Loeys-Dietz syndrome are advised to avoid contact and
    competitive sports and isometric exercise, and agents that stimulate the
    cardiovascular system including routine decongestants and triptans for
    migraine. This is the LDS-wide "agents/circumstances to avoid" guidance;
    it applies to TGFB3 carriers with demonstrated aortic involvement, and its
    applicability to the non-vascular presentation with normal serial imaging
    has not been separately studied.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Agents/circumstances to avoid: Contact sports, competitive sports, and
      isometric exercise; agents that stimulate the cardiovascular system
      including routine use of decongestants or triptan medications for the
      management of migraine headache
    explanation: >-
      GeneReviews lists the activities and agents to avoid in Loeys-Dietz
      syndrome, which includes TGFB3-related LDS type 5.
- name: Pregnancy and Peripartum Aortic Surveillance
  description: >-
    Pregnancy and the postpartum period are high-risk intervals in Loeys-Dietz
    syndrome, with increased risk of aortic dissection or rupture and of uterine
    rupture, so aortic imaging is intensified during gestation and in the weeks
    after delivery and medical therapy is reviewed for fetal safety.
  action_category: MONITORING
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  notes: >-
    Curated as management rather than as a phenotype. The evidence is
    Loeys-Dietz-syndrome-wide GeneReviews guidance covering TGFB3-related LDS
    type 5, not TGFB3-specific data. Angiotensin receptor blockers are
    contraindicated in pregnancy and must be withdrawn before or at conception;
    see the notes on "Angiotensin Receptor Blocker Therapy".
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pregnancy and the postpartum period can be dangerous for women with LDS
      because of increased risk of aortic dissection/rupture and uterine
      rupture. Increased frequency of aortic imaging is recommended, both
      during pregnancy and in the weeks following delivery.
    explanation: >-
      GeneReviews documents the peripartum aortic-catastrophe and
      uterine-rupture risk in Loeys-Dietz syndrome and the intensified imaging
      schedule it warrants.
- name: Genetic Counseling
  description: >-
    Autosomal dominant inheritance with a 50% recurrence risk for offspring, and
    a high de novo rate among Loeys-Dietz probands, make genetic counseling and
    cascade testing of at-risk relatives central to management.
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301312
    reference_title: "Loeys-Dietz Syndrome (GeneReviews)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each child of an individual with LDS has a 50% chance of inheriting the
      pathogenic variant and the disorder.
    explanation: >-
      GeneReviews states the recurrence risk that underpins genetic counseling.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    Rienhoff syndrome is ultra-rare and no population prevalence has been
    established. Two multi-family series anchor the case count: 43 patients from
    11 families ascertained from a cohort of 470 index cases with thoracic
    aortic aneurysm, and a separate Dutch-French cohort of 32 patients from 17
    families carrying 11 disease-causing variants. Additional isolated families
    and the index case have been reported separately. Because the disorder shows
    reduced penetrance, ascertained case counts almost certainly understate the
    number of variant carriers.
  evidence:
  - reference: PMID:31898322
    reference_title: "Phenotypic spectrum of TGFB3 disease-causing variants in a Dutch-French cohort and first report of a homozygous patient."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eleven (eight novel) TGFB3 disease-causing variants were identified in 32
      patients (17 families).
    explanation: >-
      Provides the second sizeable case count for TGFB3-related disease;
      population prevalence remains undetermined.
  - reference: PMID:25835445
    reference_title: "Mutations in a TGF-β ligand, TGFB3, cause syndromic aortic aneurysms and dissections."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we report on 43 patients from 11 families with syndromic
      presentations of aortic aneurysms caused by TGFB3 mutations.
    explanation: >-
      Provides the only sizeable case count available for TGFB3-related disease;
      population prevalence remains undetermined.
datasets: []

📚

References & Deep Research

References

1

PMID:20301312

Loeys-Dietz Syndrome.

No top-level findings curated for this source.

Deep Research

2

Claude Code ▸

Rienhoff Syndrome — Comprehensive Disease Characteristics Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 16 citations 2026-07-31T05:40:57.814817

Rienhoff Syndrome — Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview: Rienhoff syndrome is a rare, autosomal dominant connective tissue disorder caused by heterozygous (rarely homozygous) mutation in TGFB3 (transforming growth factor beta 3, 14q24.3). It was first described in 2013 by Hugh Young Rienhoff Jr. — a physician-scientist who used exome sequencing to identify a de novo TGFB3 mutation in his own daughter, who presented with distal arthrogryposis, hypotonia, severely reduced muscle mass, growth retardation, and a bifid uvula, but no vascular disease (Rienhoff et al. 2013, PMID:23824657). The condition is now formally catalogued as Loeys-Dietz syndrome type 5 (LDS5), the fifth and most recently delineated member of the Loeys-Dietz syndrome (LDS) family of TGF-β-pathway aortopathies (alongside LDS1/TGFBR1, LDS2/TGFBR2, LDS3/SMAD3, LDS4/TGFB2). Rienhoff syndrome/LDS5 sits within the broader clinical spectrum of syndromic heritable thoracic aortic disease that overlaps phenotypically with Marfan syndrome (OMIM #154700) and the other Loeys-Dietz syndromes (OMIM #609192 and related), but is genetically and mechanistically distinct.

Key identifiers: | Resource | Identifier | |---|---| | OMIM (phenotype) | #615582 — LOEYS-DIETZ SYNDROME 5; LDS5 | | OMIM (gene, TGFB3) | *190230 | | MONDO | MONDO:0014262 | | HGNC (gene) | HGNC:11769 (TGFB3) | | Gene location | 14q24.3 | | GARD (NIH) | GARD ID 12356 | | GTR condition | C3810012 | | ICD-10/11 | No dedicated code; typically coded under Q87.4 (Marfan syndrome) or Q87.8 (other specified congenital malformation syndromes involving the skeletal system) pending a Rienhoff/LDS5-specific ICD entry | | MeSH | Indexed under "Loeys-Dietz Syndrome" (D000073618) and "TGF-beta3 protein" — no distinct MeSH heading yet |

Synonyms: Loeys-Dietz syndrome 5 (LDS5); TGFB3-related disorder; "TGFB3 syndrome"; informally, "Rienhoff syndrome" after the discoverer. ClinVar/GeneReviews increasingly use "Loeys-Dietz syndrome 5 (LDS5)" as the preferred name, with "Rienhoff syndrome" retained as a historical/alternate label (GARD, Monarch Initiative, NORD).

Evidence base: The disease is characterized almost entirely from a small number of published individual case reports and case series (fewer than ~50 molecularly confirmed patients across ~15 families worldwide as of the largest published cohort), not from large aggregated registries — reflecting its status as an ultra-rare, recently delineated Mendelian disorder.

2. Etiology

Disease causal factor: Rienhoff syndrome/LDS5 is caused by heterozygous loss-of-function or dominant-negative pathogenic variants in TGFB3, encoding transforming growth factor beta-3, a secreted TGF-β superfamily ligand. Rienhoff et al. (2013) demonstrated the founding de novo variant reduces TGF-β signaling activity — a hypomorphic mechanism ("decreased TGF-β signaling activity of TGFB3 attributable to a loss of TGFB3 activity is a likely cause…", PMID:23824657). This is mechanistically notable because it initially appeared paradoxical relative to the "increased TGF-β signaling" paradigm established for LDS1–4 (TGFBR1/2, SMAD3) — subsequent work (Bertoli-Avella et al. 2015, PMID:25835445) showed the picture is more nuanced, with some TGFB3 variants (e.g., in the RGD integrin-binding motif or RKKR proteolytic-activation motif) instead paradoxically increasing downstream canonical TGF-β/SMAD2/3 signaling, consistent with the broader LDS mechanism.

Genetic risk factors: - Causal gene: TGFB3 (HGNC:11769; OMIM 190230), chr14q24.3. All reported cases carry heterozygous coding variants; one homozygous case has been reported (European Heart Journal 2019 international-cohort abstract, Marsili/Overwater/Maugeri et al.), presenting with aortic dilatation at age 17, splenic torsion, severe myopia, and cleft palate — suggesting gene dosage may modulate phenotype severity. - Variant spectrum: A 2018 mutation update (Schepers et al., Hum Mutat 39:621–634, PMID:29392890) catalogued 15 distinct TGFB3 mutations: ~60% missense, ~20% frameshift, ~13% nonsense, ~7% splice-site. Notably, ~35% of mutations cluster in the RKKR motif, the furin-cleavage recognition site required for proteolytic release of mature TGF-β3 from the latency-associated peptide (LAP) — a clear mutational hotspot. A recurrent p.Asp263His substitution was independently found in three patients from the same geographic region, raising a possible founder-effect hypothesis (still under investigation per the authors). - No identified susceptibility/modifier loci beyond TGFB3 itself have been reported; genetic background is known to modulate phenotype severity in the mouse knockout model (see §15), suggesting an analogous but uncharacterized modifier effect may exist in humans. - De novo occurrence:* The index/founding case (Rienhoff's daughter) arose de novo in a nonconsanguineous family with unaffected parents and two unaffected older siblings (PMID:23824657). Subsequent reported cases include both de novo and familial (vertically transmitted) occurrences (e.g., a three-generation family reported by Meienberg-adjacent exome study PMID:26184463, affecting a father and two children).

Environmental risk factors: None established; this is a purely monogenic Mendelian disorder with no known environmental, infectious, occupational, or lifestyle contributors to disease causation.

Protective factors: None specifically documented for TGFB3-related disease. No protective alleles or modifier variants reducing penetrance have been reported in the literature to date (contrast with better-characterized aortopathies where modifier loci have been proposed).

Gene-environment interactions: Not established/reported for this ultra-rare condition — the literature base (case reports/small cohorts) is too limited to have addressed G×E questions.

3. Phenotypes

Clinical expression is notably variable, ranging from a severe "forme fruste" (isolated features) to full syndromic presentation; TGFB3 is reported to show lower penetrance and expressivity than TGFBR1/2 or SMAD3 variants, particularly for the vascular phenotype (GeneReviews Loeys-Dietz Syndrome chapter). Below, phenotypes are organized by system with suggested HPO terms.

Musculoskeletal / Growth

Phenotype	HPO term (suggested)	Notes
Distal arthrogryposis	HP:0005684 (Camptodactyly of finger) / HP:0001063 (Distal arthrogryposis, general)	Presenting feature in the index case; congenital joint contractures of hands/feet
Low muscle mass / hypomyoplasia	HP:0003202 (Skeletal muscle atrophy) / HP:0001290 (Generalized hypotonia)	"Failure of normal postnatal muscle development"; muscle biopsy shows normal fiber architecture (non-dystrophic), distinguishing it from primary myopathies
Growth retardation	HP:0001510 (Growth delay)	Index patient <1st centile weight, 5th centile height at age 9
Reduced subcutaneous fat	HP:0009748 (Postnatal onset of obesity) inverse / HP:0003758 (Reduced subcutaneous adipose tissue)
Skeletal overgrowth (in other reported patients)	HP:0000098 (Tall stature)	Some patients (e.g., p.Arg300Gly family, PMID:26184463) show tall stature/arachnodactyly overgrowth rather than growth retardation — illustrating marked phenotypic heterogeneity
Arachnodactyly	HP:0001166	Reported in overgrowth-phenotype families
Pectus deformity	HP:0000768 (Pectus excavatum) / HP:0000765 (Pectus carinatum)	Frequently reported systemic feature across cohort
Joint hypermobility	HP:0001382	Frequently reported
Pes planus / clubfoot	HP:0001763 (Pes planus) / HP:0001762 (Talipes equinovarus)
Scoliosis / cervical spine instability	HP:0002650 (Scoliosis)

Craniofacial

Phenotype	HPO term	Notes
Bifid uvula	HP:0000193	Present at 17 months in index case; hard palate intact; direct evidence of TGFB3's palatogenesis role
Cleft palate	HP:0000175	Reported in a subset of patients (including the homozygous case)
High-arched palate	HP:0000218	One of the most frequently reported systemic features in the international cohort
Hypertelorism	HP:0000316	Reported in overgrowth-phenotype family

Cardiovascular

Phenotype	HPO term	Notes
Thoracic/abdominal aortic aneurysm	HP:0004942 (Aortic aneurysm) / HP:0002616 (Aortic root aneurysm)	Core feature of LDS5 as formally defined by Bertoli-Avella et al. 2015 (43 patients/11 families) — but notably absent in the original index case through age 6.5 years
Aortic/arterial dissection	HP:0002647	Risk feature; TGFB3-LDS reported to lack the striking tortuosity typical of other LDS subtypes and has less evidence for early dissection than LDS1–4
Mitral valve disease/prolapse	HP:0001633	Reported systemic feature
Cerebral/other arterial aneurysm	HP:0004944	Reported in a subset

Other

Myopia (severe) — HP:0000545 (reported in homozygous case)
Splenic torsion — reported as a rare complication in the homozygous case
Eosinophilic esophagitis / allergic diathesis (asthma, eczema) — reported in the broader LDS spectrum (per GARD summary, though this may reflect general-LDS rather than LDS5-specific data and should be verified per-patient)
Skin findings (velvety skin, easy bruising) — general-LDS feature; TGFB3-specific frequency not separately quantified in the literature reviewed

Phenotype characteristics: - Onset: Congenital/neonatal (arthrogryposis, hypotonia, bifid uvula/cleft palate present at birth or shortly after); vascular features, when present, may not manifest until later childhood or adulthood. - Severity/progression: Highly variable — muscle/growth phenotype was static-to-slowly-progressive in the index case; vascular phenotype, when present, is progressive and requires longitudinal surveillance. - Frequency: No large-cohort frequency percentages are available given the rarity of the condition (total published cases number in the dozens). The international cohort (2019) reported high-arched palate, arachnodactyly, pes planus, pectus deformity, and joint hypermobility as the most frequently reported systemic features, without a formal denominator-based percentage. - Quality of life impact: Not formally studied with validated instruments (EQ-5D, SF-36) for this specific condition; qualitatively, the index case exhibited severe generalized weakness (strength 1/5) with functional impact on mobility and growth.

4. Genetic/Molecular Information

Causal gene: TGFB3 (HGNC:11769; NCBI Gene ID 7043; OMIM *190230; chr14q24.3).

Representative pathogenic variants: | Variant (cDNA) | Protein change | Domain | Origin | Source | |---|---|---|---|---| | c.1226G>A | p.Cys409Tyr (C409Y) | Mature peptide "cysteine knot" (conserved structural motif across TGF-β family) | De novo | Rienhoff et al. 2013, PMID:23824657 | | c.898C>G | p.Arg300Gly (R300G) | Mature peptide domain | Familial (3 affected, father + 2 children) | PMID:26184463 | | c.427A>T | p.Arg143Ter (nonsense, premature stop) | Latency-associated peptide (LAP) domain | — | ClinVar RCV003050507, classified Pathogenic by Labcorp Genetics/Invitae (1-star, criteria provided); absent from gnomAD | | Various — LAP domain frameshift/nonsense | — | LAP domain | De novo | Matyas, Naef, Tollens, Oexle 2014, PMID:24798638 (letter; overgrowth + LDS-overlap phenotype); response by Rienhoff, PMID:24817670 | | RKKR-motif missense/frameshift cluster (~35% of known variants) | — | Furin-cleavage/proteolytic activation motif | Mixed | Schepers et al. 2018, PMID:29392890 | | p.Asp263His (recurrent, 3 unrelated patients) | — | — | Possible founder | Schepers et al. 2018, PMID:29392890 |

Variant classification (ACMG/AMP): Pathogenic/likely pathogenic classifications rely predominantly on de novo occurrence, absence from population databases (gnomAD), functional plausibility (loss-of-function or motif disruption), and segregation in the rare familial cases — formal multi-criteria ACMG scoring is sparsely documented in the primary literature reviewed, consistent with the rarity of the condition.

Variant type/class: Missense (60%), frameshift (20%), nonsense (13%), splice-site (7%) per the 2018 mutation update (n=15 variants) — PMID:29392890.

Allele frequency: TGFB3 pathogenic variants are essentially absent from gnomAD/population databases (explicitly noted for the c.427A>T nonsense variant in ClinVar), consistent with a rare, highly penetrant-for-molecular-phenotype but variably-expressive Mendelian disorder.

Somatic vs. germline: All reported variants are germline (constitutional), either de novo or familial.

Functional consequences: Mechanistically heterogeneous — some variants (e.g., C409Y in the cysteine knot) are hypomorphic/loss-of-function, reducing TGF-β3 ligand activity; others (e.g., variants disrupting the RGD integrin-binding motif or the RKKR proteolytic-activation site) are proposed to produce a paradoxical increase in downstream canonical (SMAD2/3-dependent) TGF-β signaling, aligning LDS5 mechanistically with LDS1–4 despite the ligand-level loss-of-function. This dual mechanism (locally reduced ligand activity vs. globally increased pathway output) is an active area of investigation and a genuine biological complexity rather than a simple unidirectional loss- or gain-of-function story.

Modifier genes: None established in humans; genetic background is documented to modulate penetrance/severity of the analogous Tgfb3-null phenotype in mice (see §15).

Epigenetic information: Not reported for this disease in the literature surveyed.

Chromosomal abnormalities: Not applicable — this is a single-gene coding-variant disorder, not a copy-number/structural disease.

Related but distinct TGFB3-associated disease: TGFB3 regulatory (promoter/UTR) mutations cause a genetically and mechanistically distinct disease, Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy 1 (ARVD1/ARVC1, OMIM #107970) (Beffagna et al. 2005, PMID:15639475). ARVD1 involves progressive fibrofatty myocardial replacement and arrhythmia risk, and is caused by regulatory rather than coding TGFB3 variants — curators should take care to distinguish ARVD1 from LDS5/Rienhoff syndrome when annotating TGFB3-gene-disease relationships, as they are separate MONDO/OMIM entities sharing one gene locus.

5. Environmental Information

No environmental factors, lifestyle factors, or infectious agents are implicated in the etiology of Rienhoff syndrome/LDS5 — it is a purely monogenic disorder. Not applicable beyond noting that, as with other heritable aortopathies, patients are counseled to avoid activities/exposures that increase hemodynamic aortic stress (isometric/high-intensity exercise) as a secondary risk-modification measure once diagnosed (general LDS management principle; not TGFB3-specific primary literature).

6. Mechanism / Pathophysiology

Molecular pathway: TGFB3 encodes a secreted TGF-β superfamily ligand. The preproprotein is proteolytically processed (furin-family protease cleavage at the RKKR motif) into a latency-associated peptide (LAP) and the mature TGF-β3 peptide; the mature peptide is held latent in a complex with LAP and latent TGF-β binding protein (LTBP1) until activated via integrin-mediated distortion of LAP or interaction with milieu molecules (LTBP1, LRRC32/GARP). Active mature TGF-β3 homodimer binds the TGFBR2/TGFBR1 receptor complex, triggering canonical SMAD2/3 phosphorylation and nuclear translocation to regulate target-gene transcription (GeneCards/UniProt synthesis).

Causal chain (proposed): 1. Trigger: Heterozygous TGFB3 coding variant (LAP domain, cysteine-knot, RGD motif, or RKKR proteolytic-activation motif). 2. Molecular consequence: Depending on variant location — either reduced mature ligand production/activity (hypomorphic; e.g., C409Y disrupting the cysteine knot) or dysregulated latent-complex processing/activation, in some cases yielding paradoxically increased canonical TGF-β/SMAD2/3 signaling output (mechanistically convergent with LDS1–4). 3. Cellular consequence: Disrupted TGF-β signaling in neural-crest-derived craniofacial mesenchyme (palatal shelf fusion) and in skeletal/vascular smooth muscle and connective tissue. 4. Tissue consequence: Failure of palatal shelf fusion (bifid uvula/cleft palate); impaired postnatal skeletal muscle development (hypomyoplasia); in a subset of patients, aortic wall extracellular matrix/smooth-muscle dysfunction leading to aneurysm formation — mechanistically analogous to (though generally milder/lower-penetrance than) the other LDS subtypes and Marfan syndrome. 5. Organismal manifestation: Distal arthrogryposis, growth retardation, low muscle mass, craniofacial anomalies, and (variably) syndromic aortic aneurysm/dissection.

Cellular processes involved: Neural crest cell migration/differentiation (craniofacial development), myogenesis (postnatal muscle growth), vascular smooth muscle cell phenotype maintenance and extracellular matrix homeostasis (aortic wall integrity) — GO:0060325 (face morphogenesis), GO:0007519 (skeletal muscle tissue development), GO:0001525 (angiogenesis-adjacent vascular processes) are plausible GO term anchors, though disease-specific single-cell/transcriptomic data are not available (see below).

Protein dysfunction: Loss-of-function (hypomorphic ligand activity) for some variants (e.g., cysteine-knot disruption); for others, disruption of the RKKR furin-cleavage or RGD integrin-binding motifs alters ligand bioavailability/activation kinetics, with a net dominant-negative or paradoxical gain-of-pathway-signaling effect at the receptor/SMAD level — this dual mechanism is explicitly discussed as an open area in Bertoli-Avella et al. 2015 (PMID:25835445) and Schepers et al. 2018 (PMID:29392890).

Metabolic changes / immune involvement: Not reported as primary disease mechanisms for Rienhoff syndrome/LDS5; this is a structural/developmental connective-tissue disorder, not a metabolic or primary immune disease (though allergic diathesis, e.g., eosinophilic esophagitis, asthma, eczema, is noted anecdotally in the broader LDS phenotype spectrum per GARD — mechanism not established as TGF-β-driven immune dysregulation specifically in LDS5).

Tissue damage mechanisms: Aortic wall — smooth-muscle/ECM dysfunction predisposing to medial degeneration and aneurysm (the shared LDS/Marfan-spectrum mechanism, per the dismech aortopathy_tgfbeta_dysregulation module framework — TGFB3 fits as an additional causal-lesion substitution alongside FBN1/TGFBR1/TGFBR2/SMAD3/TGFB2/COL3A1/SLC2A10/ACTA2 etc.). Skeletal muscle — non-dystrophic hypomyoplasia (normal fiber architecture on biopsy, distinguishing the mechanism from primary dystrophic myopathies).

Biochemical abnormalities: No specific enzyme deficiency or receptor-channel defect; the core biochemical lesion is dysregulated TGF-β3 ligand processing/activity.

Molecular profiling / advanced technologies: No transcriptomic, proteomic, metabolomic, single-cell, or spatial-omics datasets specific to human Rienhoff syndrome/LDS5 patient tissue were identified in this search. Mouse Tgfb3-knockout palatal-shelf transcriptomic data exist (RNA-seq analyses of Tgfb3-knockout palatal transcriptome — e.g., PMC3618314, PMC7483747, Sci Rep 2020) and could serve as an animal-model molecular-profiling proxy, though translational fidelity to the human coding-variant disease (vs. complete null) should be treated cautiously (a candidate HUMAN_MODEL_MISMATCH consideration for dismech curation, given the knockout model is a complete loss-of-function whereas most human variants are heterozygous/hypomorphic).

7. Anatomical Structures Affected

Organ level: - Primary: Musculoskeletal system (skeletal muscle, joints — arthrogryposis), craniofacial skeleton/soft palate, aorta/great vessels (when vascular phenotype present). - Secondary: Mitral valve, cervical spine, feet (clubfoot/pes planus), spleen (torsion reported in one case), eye (severe myopia in one case). - Body systems: Musculoskeletal, craniofacial/orofacial, cardiovascular, and (variably) ocular.

Tissue/cell level: - Skeletal muscle fibers (Type I/II, non-dystrophic pattern on biopsy) — relevant CL term: CL:0000188 (skeletal muscle myoblast) / CL:0008002 (skeletal muscle fiber). - Palatal shelf mesenchyme (cranial neural crest-derived) — CL:0000333 (neural crest cell). - Aortic medial smooth muscle cells and adventitial fibroblasts — CL:0002591 (smooth muscle cell of the pulmonary artery is a near analog; more precisely CL:0000359, vascular associated smooth muscle cell) and CL:0000057 (fibroblast).

Subcellular level: Extracellular (secreted ligand) — GO:0005615 (extracellular space); latent TGF-β complex assembly in the ER/Golgi during preproprotein processing — GO:0005788 (endoplasmic reticulum lumen), GO:0000139 (Golgi membrane).

Localization (UBERON): - UBERON:0001630 (skeletal muscle tissue) - UBERON:0002499 (secondary palate) / UBERON:0002501 (uvula) - UBERON:0001496 (aorta) / UBERON:0009835 (aortic root) - UBERON:0002349 (myocardium/mitral valve region — UBERON:0002143, mitral valve) - UBERON:0002037 (cerebellum — not implicated); more relevantly UBERON:0001981 (blood vessel) generally for the vascular phenotype.

Lateralization: Generally bilateral/symmetric (arthrogryposis, muscle hypoplasia); aortic involvement is midline/central vascular structure, not lateralized.

8. Temporal Development

Onset: Congenital — arthrogryposis, hypotonia, and bifid uvula are present at birth or in early infancy (bifid uvula confirmed at 17 months in the index case). Growth retardation becomes evident in early childhood. Vascular (aortic) features, when present, may not manifest until later childhood, adolescence, or adulthood — echocardiographic surveillance in the index case showed no cardiac/aortic abnormality through age 6.5 years, whereas the reported homozygous patient had aortic dilatation by age 17.
Onset pattern: Insidious/static for the musculoskeletal phenotype (present from birth, then relatively stable through the observation period); potentially progressive for the vascular phenotype in patients who develop it.
Disease stages: No formal staging system exists (unlike, e.g., cancer). Clinically relevant "checkpoints" are pediatric surveillance milestones (growth/muscle assessment) and periodic aortic imaging (echocardiogram/MRI/CT per general LDS surveillance protocols).
Progression rate: Variable — some patients remain stable without vascular disease into at least mid-childhood (index case); others (e.g., homozygous case) show earlier and more severe vascular involvement.
Disease course pattern: Chronic, lifelong; not relapsing-remitting. No documented spontaneous remission.
Critical periods: Prenatal/early embryonic palatal-shelf fusion window (relevant to cleft palate/bifid uvula pathogenesis, informed by the Tgfb3-knockout mouse developmental timing) and childhood/adolescent growth window (muscle development).

9. Inheritance and Population

Epidemiology: No disease-specific prevalence/incidence estimate exists for Rienhoff syndrome/LDS5 given its extreme rarity (total published molecularly confirmed cases number in the dozens, from ~15 kindreds as of the largest cohort reviews). By analogy, Loeys-Dietz syndrome overall (all 5 genetic subtypes combined) is estimated at roughly 1:25,000–1:100,000, though these figures are considered underestimates given historical underdiagnosis and phenotypic overlap with Marfan and Ehlers-Danlos syndromes; LDS5/TGFB3 represents a small minority subset of this already-rare group.

Inheritance pattern: Autosomal dominant. Both de novo occurrence (the index case, and several subsequently reported patients) and vertical familial transmission (e.g., father-to-two-children transmission in PMID:26184463) have been documented. One homozygous patient has been reported (European Heart Journal 2019 international-cohort report), raising the possibility of a gene-dosage effect, though this remains a single-case observation.

Penetrance: Notably reduced/variable, and explicitly reported as more common (non-penetrance) in TGFB2/3 families than in TGFBR1/2 families (Schepers et al. 2018, PMID:29392890) — i.e., obligate carriers may show minimal or no clinical phenotype, particularly for the vascular component.

Expressivity: Highly variable, even within families — phenotypes range from isolated skeletal-muscle/growth features without vascular disease (index case) to classic syndromic aortic aneurysm presentations (Bertoli-Avella cohort) to an overgrowth phenotype with tall stature and arachnodactyly (PMID:26184463) rather than growth retardation. "Forme fruste" (partial/isolated feature) presentations are reported to be more common than the full syndromic LDS5 picture.

Genetic anticipation: Not reported/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed, though theoretically possible for any de novo autosomal dominant disorder; recurrence-risk counseling would conventionally include a residual mosaicism-based recurrence risk in future pregnancies for families with an apparently de novo proband.

Founder effects: A possible founder mutation (p.Asp263His, found in three unrelated patients from the same geographic region) is proposed but explicitly flagged by the authors as "currently under investigation" (PMID:29392890) — this should be treated as a hypothesis, not established fact.

Consanguinity: The one reported homozygous case would be consistent with either consanguinity or two independent variant alleles — specific parental consanguinity status was not detailed in the search results retrieved; this would need primary-source verification before curation.

Carrier frequency / population demographics: No population-specific carrier frequency has been established; TGFB3 pathogenic variants are essentially absent from gnomAD. No specific ethnic or geographic predilection has been established beyond the founder-mutation hypothesis noted above. Sex ratio and age-distribution data are not separately reported for TGFB3/LDS5 (small case-series sizes preclude robust demographic statistics).

10. Diagnostics

Clinical/laboratory tests: No specific biochemical or enzymatic biomarker exists; diagnosis relies on clinical phenotype recognition plus molecular confirmation. Standard connective-tissue-disorder workup (echocardiography, skeletal survey, ophthalmologic exam) parallels Marfan/LDS diagnostic pathways.

Imaging: - Echocardiography — first-line and serial surveillance for aortic root/ascending aorta dimensions. - MRI/CT angiography (head-to-pelvis) — for comprehensive arterial tree surveillance (cerebral through iliac vessels), per general LDS management principles (GeneReviews Loeys-Dietz Syndrome chapter; ACC/AHA 2022 Aortic Disease Guideline). - Skeletal radiographs — for scoliosis/spine (e.g., the 2023 case report documented thoracolumbar scoliosis with Cobb angle 53°, sacroiliac/pubic symphysis degenerative changes, and femoral head-neck osteophytosis — Ann Intern Med Clin Cases 2023).

Biopsy findings: Skeletal muscle biopsy in the index case showed a normal checkerboard fiber pattern without dystrophic changes (no endomysial fibrosis, no marked fiber-size disproportion) — an important distinguishing feature from primary dystrophic myopathies and from Marfan-syndrome-associated myopathy.

Genetic testing: - Single-gene TGFB3 sequencing or multi-gene aortopathy/connective-tissue panels (including FBN1, TGFBR1, TGFBR2, SMAD3, TGFB2, COL3A1, ACTA2, MYH11, etc.) are the standard approach given phenotypic overlap with Marfan/other LDS subtypes. - Whole-exome sequencing (WES) was the discovery method for the index case and several subsequent cases (Rienhoff et al. 2013; PMID:26184463) and remains clinically useful when panel testing is uninformative or the phenotype is atypical. - No specific CMA, karyotype, FISH, mitochondrial, or repeat-expansion testing role — this is a coding single-nucleotide/small-indel disorder in a single gene.

Differential diagnosis: Marfan syndrome (FBN1), Loeys-Dietz syndromes 1–4 (TGFBR1, TGFBR2, SMAD3, TGFB2), vascular Ehlers-Danlos syndrome (COL3A1), Shprintzen-Goldberg syndrome, and other distal arthrogryposis syndromes (for the neonatal presentation) — genetic testing is required to distinguish, given overlapping craniofacial, skeletal, and vascular features.

Screening: No population or newborn screening program exists (as expected for an ultra-rare Mendelian disorder); cascade family testing is appropriate once a proband is molecularly confirmed, given autosomal dominant inheritance with reduced penetrance.

11. Outcome/Prognosis

No formal survival, mortality, or validated quality-of-life statistics specific to Rienhoff syndrome/LDS5 exist in the literature reviewed (case-report-level evidence only). Prognosis is believed to be more favorable than the classic Marfan/LDS1-2 vascular phenotype given the generally lower penetrance and lesser aortic tortuosity/dissection risk reported for TGFB3-related disease compared with TGFBR1/2 and SMAD3 (GeneReviews). However, given the reported homozygous case with early (age 17) aortic dilatation and the general LDS literature establishing risk of dissection/rupture at smaller aortic diameters than typical atherosclerotic aneurysms, patients require lifelong cardiovascular surveillance. Musculoskeletal morbidity (muscle weakness/hypomyoplasia, joint contractures) can be functionally significant, as illustrated by the severe (1/5 strength) presentation in the index case. Losartan trial in the index case reportedly showed no clinical benefit for the muscle/growth phenotype (as would be expected, since losartan targets TGF-β vascular signaling rather than the myogenic mechanism).

12. Treatment

Pharmacotherapy: No TGFB3/Rienhoff-syndrome-specific approved drug exists. Management follows general LDS/Marfan-spectrum aortopathy guidelines: - Angiotensin receptor blockers (ARBs) — e.g., losartan (suggested MAXO: MAXO:0000647 is not applicable; better MAXO/NCIT: NCIT:C15986 Pharmacotherapy + therapeutic_agent CHEBI losartan) — first-line for aortic-root growth-rate reduction in mouse LDS models and widely used clinically, though the index case's losartan trial for the muscle phenotype was not beneficial (expected, given the drug targets vascular TGF-β signaling). - Beta-blockers (e.g., atenolol, propranolol, metoprolol) — used in combination with or as alternative to ARBs for hemodynamic aortic-wall-stress reduction.

Surgical/interventional: Prophylactic aortic root/ascending aorta repair, timed by aortic diameter, growth rate, genotype, extra-aortic features, age, sex, and family history, per the 2022 ACC/AHA Aortic Disease Guideline (general LDS-spectrum recommendation, not TGFB3-specific) — MAXO:0000004 (surgical procedure) / NCIT:C15329 (Surgical Procedure). Orthopedic surgical correction (e.g., for clubfoot, scoliosis) — NCIT:C16186 (Orthopedic Surgical Procedure).

Supportive/rehabilitative: Physical therapy (MAXO:0000011) for joint contractures/muscle weakness; nutritional support for growth retardation; genetic counseling (MAXO:0000079) for at-risk family members given autosomal dominant inheritance with reduced penetrance.

Surveillance ("treatment strategy"): Serial echocardiography (yearly, as performed in the index case from 18 months of age) plus periodic comprehensive vascular imaging (MRI/CT head-to-pelvis) per general LDS protocols; increased imaging frequency during pregnancy and the postpartum period given elevated dissection risk in that window (general LDS/Marfan obstetric management principle).

Experimental/investigational: No TGFB3/Rienhoff-syndrome-specific clinical trials were identified. A general LDS-relevant trial, "Immunopathology of Loeys-Dietz Syndrome" (NCT05472519), is ongoing but not TGFB3-subtype-specific.

Personalized/genotype-guided approach: Management guidelines explicitly note that surgical thresholds and surveillance intervals should be genotype-informed, with TGFB3/LDS5 generally considered lower-risk for early dissection/tortuosity than TGFBR1/2-driven disease — supporting a somewhat less aggressive surgical threshold in appropriately counseled patients, though this should always be individualized.

13. Prevention

No primary prevention exists (monogenic disorder). Secondary prevention centers on early molecular diagnosis (cascade genetic testing of at-risk relatives given autosomal dominant inheritance with reduced penetrance) enabling early initiation of cardiovascular surveillance before symptomatic aortic disease develops. Tertiary prevention consists of the surveillance/medical-therapy/surgical-threshold protocols described in §12 to prevent dissection/rupture in individuals with confirmed pathogenic variants. Genetic counseling is a core component given the 50% transmission risk per pregnancy for an affected parent, tempered by counseling about reduced penetrance and highly variable expressivity (a family member may carry the variant with minimal or no clinical phenotype). Prenatal/preimplantation genetic testing is theoretically available once a familial variant is identified, though not specifically reported as utilized in the literature reviewed for this condition specifically.

14. Other Species / Natural Disease

No naturally occurring TGFB3-coding-variant disease analogous to human Rienhoff syndrome/LDS5 has been reported in companion animals or wildlife (no OMIA entry identified in this search). TGFB3 is highly conserved across mammals (orthologous gene present in mouse Tgfb3, used extensively in knockout studies — see §15); no veterinary/naturally-occurring disease counterpart is documented, distinguishing this from diseases with established OMIA veterinary correlates.

15. Model Organisms

Mouse (Mus musculus) — Tgfb3 knockout, the primary and most extensively characterized model:

Proetzel et al. 1995 ("Transforming growth factor-β3 is required for secondary palate fusion," Nature Genetics 11:409–414, PMID:7493021): Tgfb3-null mice (exon 6 replaced by neomycin-resistance cassette) show incompletely penetrant failure of palatal shelf fusion → cleft palate, directly recapitulating the human bifid uvula/cleft palate phenotype.
Kaartinen et al. 1995 ("Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction," Nature Genetics 11:415–421): Homozygous Tgfb3-null mice show defective palatogenesis plus a consistent delay in pulmonary development, an additional phenotype not prominently reported in human patients (a candidate HUMAN_MODEL_MISMATCH point — the mouse pulmonary phenotype has not been clearly corroborated in human TGFB3 patients in the literature reviewed).
Pathogenesis-of-cleft-palate mechanistic study (PMID:10433915) further characterized the cellular mechanism of medial-edge-epithelium persistence/failure of disintegration underlying the cleft phenotype.
Genetic-background-dependence study (Nakamura lab et al., PMID:32603777): demonstrated that genetic background strongly modulates the penetrance and severity of the cleft-palate phenotype in Tgfb3-knockout mice — directly relevant background for interpreting the reduced/variable penetrance seen in human TGFB3 pedigrees, and a useful cross-species mechanistic parallel (though not proof of an identical modifier mechanism in humans).
Rescue experiment: Tgfb1 knocked into the Tgfb3 locus partially rescues the cleft palate phenotype of Tgfb3-null mutants (PMC2174429), indicating partial functional redundancy among TGF-β family ligands during palatogenesis, and offering a mechanistic clue as to why some human patients with only partial TGFB3 loss-of-function show milder/incomplete palatal phenotypes.
Cardiovascular role: A dedicated review, "Transforming Growth Factor Beta3 is Required for Cardiovascular Development" (PMC7344558), synthesizes TGFB3's role in balancing canonical/non-canonical TGF-β signaling for normal cardiovascular morphogenesis — directly relevant background for the human aortic-aneurysm arm of LDS5.

Model limitations: The mouse Tgfb3-knockout is a complete null (biallelic loss-of-function), whereas essentially all human Rienhoff syndrome/LDS5 patients are heterozygous (with one reported homozygous exception), and human coding variants are often hypomorphic or motif-specific (RKKR, RGD, cysteine-knot) rather than complete nulls. The mouse model's prominent pulmonary developmental delay phenotype also lacks clear human correlation. These distinctions argue for caution in directly extrapolating full knockout-mouse severity/phenotype spectrum to the human heterozygous disease — an appropriate HUMAN_MODEL_MISMATCH framing if this disease is curated into dismech, given genuine translational-validity uncertainty (particularly for the pulmonary phenotype) alongside strong validation for the palatal/craniofacial mechanism.

No zebrafish, Drosophila, C. elegans, or iPSC/organoid model specific to TGFB3/Rienhoff syndrome was identified in this search — the mouse germline knockout remains the dominant and best-characterized model system for this gene-phenotype relationship.

Summary of Key Citations

PMID / ID	Citation
23824657	Rienhoff HY Jr et al. Am J Med Genet A. 2013;161A(8):2040-6. Original description; index case, C409Y variant.
24798638	Matyas G, Naef P, Tollens M, Oexle K. Am J Med Genet A. 2014. LAP-domain de novo TGFB3 mutation, overgrowth/LDS-overlap.
24817670	Rienhoff HY Jr. Response letter, Am J Med Genet A. 2014.
25835445	Bertoli-Avella AM, Gillis E, Morisaki H, et al. J Am Coll Cardiol. 2015;65(13):1324-1336. 43 patients/11 families; establishes LDS5 nomenclature and vascular phenotype.
26184463	Mol Cell Probes. 2015;29(5):330-4. c.898C>G/p.Arg300Gly familial overgrowth phenotype.
29392890	Schepers D et al. Hum Mutat. 2018;39:621-634. Mutation update — variant spectrum, RKKR hotspot, reduced penetrance.
15639475	Beffagna G et al. Cardiovasc Res. 2005. TGFB3 regulatory mutations → ARVD1 (distinct disease, same gene).
7493021	Proetzel G et al. Nat Genet. 1995;11:409-414. Tgfb3-null mouse, cleft palate.
Nat Genet. 1995;11:415-421	Kaartinen V et al. Tgfb3-null mouse, cleft palate + lung developmental delay (PMID not independently confirmed in this search — verify before citing in a curated entry).
32603777	Genetic background modulates Tgfb3-knockout cleft-palate penetrance.
European Heart Journal 2019;40(Suppl 1):ehz746.1087	Marsili L, Overwater E, et al. International cohort + first homozygous LDS5 patient (conference abstract; full peer-reviewed publication not independently located in this search — verify before citing).
OMIM #615582	Loeys-Dietz Syndrome 5; LDS5.
OMIM *190230	TGFB3 gene entry.
MONDO:0014262	Rienhoff syndrome.

Curation note (dismech-specific): Given the phenotypic and mechanistic overlap with the existing aortopathy_tgfbeta_dysregulation module (which already covers FBN1/TGFBR1/TGFBR2/SMAD3/TGFB2/COL3A1/SLC2A10/ACTA2/MYH11/MYLK/PRKG1), TGFB3/Rienhoff syndrome would be a natural additional conforms_to substitution for that module's "TGF-beta Signaling Dysregulation" node for the vascular-phenotype arm — while the palatogenesis/myogenesis arm (bifid uvula, hypomyoplasia) represents a distinct, TGFB3-specific mechanistic thread not covered by that module and would need its own pathophysiology nodes. The dual/paradoxical signaling mechanism (locally hypomorphic ligand vs. globally increased pathway output) and the reduced-penetrance/variable-expressivity pattern are both points meriting explicit mechanistic_hypotheses / discussion framing rather than a single confident causal-chain assertion, given how thin the primary evidence base still is for this ultra-rare, recently delineated disorder.

OpenScientist ▸

Key Findings

openscientist-autonomous 2026-07-31T06:03:26.847643

Key Findings

1. Disease Information

Rienhoff syndrome is a syndromic heritable thoracic aortic disease (H-TAD) and connective-tissue disorder that overlaps clinically with both Marfan syndrome and other Loeys-Dietz syndromes. It is defined molecularly by pathogenic variation in TGFB3.

Key identifiers:

Resource	Identifier
MONDO	MONDO:0014262 (primary label: "Rienhoff syndrome")
OMIM (disease)	#615582 (Loeys-Dietz syndrome 5)
OMIM (gene)	190230 (TGFB3*)
DOID	DOID:0070236
EFO	EFO:1000012
UMLS	C3810012
MedGen	816342
GARD	0012356
HGNC (gene)	HGNC:11769
Cytoband	14q24.3

Synonyms: Loeys-Dietz syndrome 5; Loeys-Dietz syndrome type 5; LDS5; TGFB3-related connective tissue disorder; MFS/LDS-overlap syndrome.

The Monarch Disease Ontology official definition (F011) reads: "Loeys-Dietz syndrome-5 (LDS5), also known as Rienhoff syndrome, is characterized by syndromic presentation of aortic aneurysms involving the thoracic and/or abdominal aorta, with risk of dissection and rupture. Other systemic features include cleft palate, bifid uvula, mitral valve disease, skeletal overgrowth, cervical spine instability, and clubfoot deformity; however, not all clinical features occur in all patients. In contrast to other forms of LDS, no striking aortic or arterial tortuosity is present in these patients, and there is no strong evidence for early aortic dissection."

Information for this entry is derived predominantly from aggregated disease-level resources (OMIM, MONDO, Orphanet) and from individual/small-cohort patient reports in the primary literature (Rienhoff 2013; Matyas 2014; Kuechler 2015; Marsili 2020; Mégarbané 2020), given the disorder's rarity.

2. Etiology

Primary cause — genetic. Rienhoff syndrome is a monogenic Mendelian disorder caused by heterozygous pathogenic variants in TGFB3 (F001, F008). There is no environmental or infectious etiology; the disease is fully genetically determined, though phenotypic expression is variable. A gene-dosage effect exists: biallelic (homozygous) loss produces a markedly more severe phenotype (F003, F007).

Genetic risk factors. The causal variant in TGFB3 is the sole established genetic determinant. Reported variants span: - Loss-of-function missense: c.1226G>A (p.Cys409Tyr) — the original Rienhoff 2013 index variant, associated with growth retardation. - Codon 300 hotspot (recurrent): c.899G>A (p.Arg300Gln; Matyas 2014, associated with overgrowth) and c.898C>G (p.Arg300Gly; Kuechler 2015) (F001, F014). - Structural/homozygous: a homozygous deletion of exons 2–7 causing severe LDS5 with cleft palate (Mégarbané 2020) (F003, F006).

Environmental risk factors. No specific environmental triggers cause the disease. However, general aortopathy risk modifiers apply to cardiovascular expression: hypertension and smoking are emphasized as modifiable risks for arterial events across the H-TAD spectrum (Calderon-Martinez et al. 2025 recommend "smoking cessation and hypertension control"). Pregnancy imposes hemodynamic stress that can precipitate aortic events in aortopathies generally, though no pregnancy-related deaths occurred in the Marsili cohort (F002).

Protective factors. No specific genetic or environmental protective alleles have been identified for Rienhoff syndrome. Blood-pressure control and activity/hemodynamic-stress reduction are protective against downstream aortic complications (F004).

Gene-environment interactions. The principal interaction is between the genetic TGF-β signaling defect and hemodynamic wall stress: AngII/AT1R signaling amplifies the underlying TGF-β dysregulation to drive postnatal aneurysm progression (F013). This gene–environment (hemodynamic) interaction is the target of pharmacotherapy.

3. Phenotypes

The phenotypic spectrum (F002) is dominated by systemic connective-tissue features, with cardiovascular disease that is variable and generally milder/later than classic LDS. Frequencies below are from Marsili et al. 2020 (32 patients, 17 families) unless noted.

Phenotype	Frequency	Type	Suggested HPO
High-arched palate	65%	Physical/craniofacial	HP:0000218
Arachnodactyly	63%	Physical/skeletal	HP:0001166
Pectus deformity	57%	Physical/skeletal	HP:0000766
Joint hypermobility	52%	Physical/musculoskeletal	HP:0001382
Mitral valve disease	32%	Clinical sign/cardiovascular	HP:0001633 / HP:0001634
Aortic root dilatation	29%	Clinical sign/cardiovascular	HP:0002616
Aortic disease overall (dilatation/dissection)	35%	Clinical sign	HP:0002616 / HP:0002647
Bifid/broad uvula	Reported	Physical/craniofacial	HP:0000193
Hypertelorism	Reported	Physical/craniofacial	HP:0000316
Cleft palate (esp. homozygous)	Rare/severe	Physical/craniofacial	HP:0000175
Tall stature / skeletal overgrowth	Variable	Physical	HP:0000098
Growth retardation / short stature	Variable (allele-dependent)	Physical	HP:0004322
Clubfoot (talipes)	Reported	Physical	HP:0001762
Cervical spine instability	Reported	Physical	HP:0003316
Distal aortic dissection	2 patients (ages 50, 52)	Clinical event	HP:0002647

Phenotype characteristics. Onset is congenital for craniofacial/skeletal features; cardiovascular manifestations are typically later-onset and slowly progressive, with the two documented distal dissections occurring in the sixth decade (ages 50 and 52) — notably later than classic LDS. Severity is variable, ranging from mild marfanoid habitus to severe homozygous presentations with cleft palate. Progression of aortic disease is generally slow/progressive with imaging-detectable dilatation. Incomplete penetrance and variable expressivity are documented within families (F007).

A striking allele-specific phenotype is the bidirectional stature effect (F014): the loss-of-function p.Cys409Tyr allele produced growth retardation, whereas the codon-300 p.Arg300Gln allele produced overgrowth, yet both share the marfanoid connective-tissue phenotype.

Quality of life. No Rienhoff-specific QoL data exist. By analogy to the closely related Marfan population (Pediatric Heart Network cohort; PMID 30270167), children/adolescents with marfanoid connective-tissue disease are at high risk of impaired health-related quality of life, driven more by patient-reported symptoms and neurodevelopmental comorbidity than by aortic-root severity. This is an inference from an allied disease, not direct Rienhoff data.

4. Genetic / Molecular Information

Causal gene: TGFB3 (transforming growth factor beta-3), HGNC:11769, 14q24.3, OMIM *190230 (F001, F008). TGFB3 is one of six genes converging on TGF-β signaling that cause the LDS spectrum, alongside TGFBR1, TGFBR2, TGFB2, SMAD2, and SMAD3 (F008).

Pathogenic variant classes: - Missense (most common): p.Cys409Tyr (c.1226G>A), p.Arg300Gln (c.899G>A), p.Arg300Gly (c.898C>G). - Structural/CNV: homozygous deletion of exons 2–7 (Mégarbané 2020). - Variants are classified per ACMG/AMP criteria; automated frameworks such as HTAADVar assist interpretation (F006).

Codon Arg300 is a recurrent mutational hotspot (F014). Kuechler et al. 2015 concluded that "the mutations at codon Arg300 presumably lead to increased TGF-beta signalling."

Functional consequences. The apparent paradox of the disorder: many variants (including the index LoF allele) reduce ligand production or function, yet the net tissue effect is paradoxically increased TGF-β/SMAD2 signaling in the aortic wall (F013, F014). This mirrors the mechanism in receptor-based LDS, where LoF receptor mutations nonetheless yield elevated downstream signaling.

Allele frequency. Causal variants are private/ultra-rare and absent from population databases (e.g., the original UTR ARVD1 variants were absent in 300 controls; F009). No common susceptibility alleles are established.

Somatic vs germline. All disease-causing variants are germline (inherited or de novo). No somatic mechanism is implicated in the Mendelian disorder.

Modifier genes. No specific modifier genes have been validated for Rienhoff syndrome. Gene dosage itself (mono- vs biallelic) is the strongest severity modifier (F007).

Epigenetic information. No disease-specific DNA-methylation or histone signatures have been reported for Rienhoff syndrome. (KDM5A-mediated regulation of TGFB3 has been described in the context of general cardiac fibrosis — PMID 35845066 — but not linked to Rienhoff pathogenesis.)

Chromosomal abnormalities. Aside from the intragenic exon 2–7 deletion, no recurrent large-scale chromosomal rearrangements define the disorder. Multigene panels increasingly include CNV/deletion–duplication analysis because ~9% of pathogenic H-TAD variants are CNVs invisible to routine NGS (F006).

Allelic disorder — ARVD1 (F009). Distinct, regulatory (UTR) gain-of-function variants in TGFB3 cause Arrhythmogenic Right Ventricular Cardiomyopathy type 1 (ARVD1) — a separate phenotype from the coding-region LDS5/Rienhoff variants. Beffagna et al. 2005 identified a 5′UTR c.-36G>A variant co-segregating across a 38-member ARVC family and a second 3′UTR c.1723C>T variant, both absent from 300 controls; mutated UTRs were "twofold more active than wild-types," indicating a gain-of-function (increased TGF-β3 expression) mechanism producing fibro-fatty replacement of the right-ventricular myocardium.

5. Environmental Information

There are no established environmental, lifestyle, or infectious causes of Rienhoff syndrome — it is a purely genetic Mendelian disorder. Environmental factors act only as modifiers of cardiovascular expression: uncontrolled hypertension, smoking, strenuous isometric activity, and the hemodynamic stress of pregnancy increase the risk of aortic/arterial events across the H-TAD spectrum (F004; Calderon-Martinez 2025; PMID 41369177). No infectious agents are relevant.

6. Mechanism / Pathophysiology

Molecular pathway — TGF-β/SMAD signaling. The unifying mechanism across all LDS subtypes, including Rienhoff/LDS5, is dysregulation of the TGF-β signaling cascade (F008). TGFB3 encodes a TGF-β ligand; its variants disturb signaling through the TGFBR1/TGFBR2 receptor complex and downstream SMAD2/SMAD3 effectors.

The central paradox. Despite loss-of-function ligand variants, aortic-wall tissue exhibits paradoxically increased TGF-β signaling. In LDS knockin mouse models, aortic Smad2 phosphorylation and TGF-β target-gene output rise progressively and postnatally, paralleling aneurysm worsening (Gallo et al. 2014, F013).

AngII/AT1R amplification (upstream driver of aortopathy). Angiotensin II type 1 receptor (AT1R) signaling enhances the TGF-β pathology. Losartan's therapeutic benefit "correlated with suppression of Smad2 phosphorylation and TGF-β1 expression," directly linking AngII-dependent TGF-β signaling to postnatal aneurysm progression (F013). This positions AngII/AT1R upstream and SMAD2-mediated matrix/vascular remodeling downstream.

Causal chain (aortic arm):

TGFB3 pathogenic variant
│  (altered ligand -> paradoxical pathway dysregulation)
v
Increased TGF-b / SMAD2-3 signaling in aortic wall
│  <- amplified by AngII / AT1R (hemodynamic stress)
v
Medial degeneration, ECM remodeling (elastin fragmentation, MMP activity)
│
v
Aortic root dilatation -> aneurysm -> (late) dissection

Causal chain (craniofacial arm):

TGFB3 loss of function
│
v
Failure of palatal medial-edge-epithelium (MEE) fusion
   (periderm not removed: TGFb3 -> IRF6 -> dNp63 pathway fails)
v
Cleft palate / bifid uvula / high-arched palate

Cellular processes. Vascular smooth muscle cell dysfunction, extracellular-matrix (elastin) degradation via matrix metalloproteinases, and apoptosis are core cellular events in the allied MFS/LDS aortic wall (miR-29b–mediated apoptosis and MMP-2 activation; PMID 22116819). In the palate, epithelial differentiation and periderm desquamation via the TGFβ3→IRF6→ΔNp63 axis are the key processes (F012).

Protein dysfunction. Altered TGF-β3 ligand function (loss-of-function coding variants; gain-of-function regulatory/UTR variants in the allelic ARVD1) (F001, F009, F014).

Immune/inflammatory involvement (under-recognized, F010). TGF-β-pathway LDS disorders predispose to allergic/immune disease. Frischmeyer-Guerrerio et al. 2013 showed LDS patients are "strongly predisposed to develop allergic disease, including asthma, food allergy, eczema, allergic rhinitis, and eosinophilic gastrointestinal disease," with elevated IgE, eosinophilia, and TGF-β-driven TH2 skewing of naïve CD4+ T cells. This immune dimension is plausibly shared by TGFB3/Rienhoff, though direct Rienhoff-specific data are lacking.

Tissue-damage mechanism: medial degeneration/cystic medial necrosis with elastin fragmentation and fibrosis of the aortic wall.

Suggested ontology terms: - GO biological processes: transforming growth factor beta receptor signaling pathway (GO:0007179); SMAD protein signal transduction (GO:0060395); regulation of extracellular matrix organization (GO:1903053); palate development (GO:0060021); aorta development (GO:0035904). - GO cellular components: extracellular matrix (GO:0031012); extracellular space (GO:0005615). - CL cell types: vascular smooth muscle cell (CL:0000359); fibroblast (CL:0000057); epithelial cell (CL:0000066); CD4-positive helper T cell (CL:0000492).

7. Anatomical Structures Affected

Organ / body-system level: - Cardiovascular (primary): aortic root and thoracic aorta (UBERON:0000947 aorta; UBERON:0004178 aortic root), mitral valve (UBERON:0002135), arch/cerebral vessels. - Craniofacial / digestive-upper: secondary palate (UBERON:0001716), uvula (UBERON:0010056). - Musculoskeletal: long bones/digits (arachnodactyly), thoracic cage (pectus), joints, cervical spine. - Ocular: notably spared of ectopia lentis (a key discriminator from Marfan syndrome).

Tissue/cell level: connective tissue broadly; aortic tunica media (vascular smooth muscle + elastic ECM); palatal medial-edge epithelium/periderm. Cell Ontology: vascular smooth muscle cell (CL:0000359); fibroblast (CL:0000057).

Subcellular level: the extracellular matrix and extracellular space are the principal compartments of dysfunction (secreted TGF-β3 ligand; ECM elastin/fibrillin scaffolds). GO cellular component: extracellular matrix (GO:0031012).

Localization / lateralization: aortic and skeletal involvement is typically bilateral/central (axial); craniofacial midline structures (palate, uvula) are affected. In contrast to LDS1/2, no striking arterial tortuosity and low extra-aortic aneurysm burden (F005, F011).

8. Temporal Development

Onset. Craniofacial and skeletal features are congenital. Cardiovascular disease is later-onset and often insidious. The disorder's defining temporal distinction from classic LDS is the absence of strong evidence for early aortic dissection (F011); documented distal dissections occurred at ages 50 and 52 (F002).

Progression. Aortic disease is slowly progressive with imaging-detectable root dilatation; overall the natural history is chronic and lifelong. Progression rate is variable and generally slower than LDS1/2. Extra-aortic arterial aneurysms, when they occur, present at a median age of ~40 years and cluster in arch vessels/cerebral circulation (F005).

Patterns / critical periods. The critical intervention window is the period of hemodynamic-driven aneurysm progression, during which pharmacologic suppression of AngII/TGF-β signaling and imaging surveillance can alter outcomes (F004, F013). Prophylactic surgery is timed to aortic-diameter thresholds (see §12).

9. Inheritance and Population

Epidemiology. Rienhoff/LDS5 is ultra-rare — one of the rarest LDS subtypes, with only roughly 30–60 reported families as of ~2020 (F007). No established prevalence or incidence figures exist.

Inheritance (F007). Autosomal dominant with incomplete penetrance and variable expressivity; both inherited and de novo variants occur. A gene-dosage effect is documented — the first-described homozygous patient "presented with a more severe phenotype compared to her heterozygous relatives" (F007), and biallelic loss produces severe LDS5 with cleft palate (F003).

Penetrance: incomplete.
Expressivity: highly variable (including bidirectional stature effects, F014).
Genetic anticipation: not applicable (not a repeat-expansion disorder).
Germline mosaicism: not specifically documented.
Founder effects / consanguinity: the homozygous case implies a role for consanguinity in severe biallelic presentations; no founder alleles established.
Carrier frequency: not established (ultra-rare, dominant).

Population demographics. No ethnic predilection, geographic clustering, or sex-ratio skew has been established given the small number of families. Age distribution spans congenital (craniofacial) to late-adult (cardiovascular) presentation.

10. Diagnostics

Molecular diagnosis is definitive and is made by next-generation sequencing multigene H-TAD panels covering FBN1, TGFBR1, TGFBR2, TGFB2, TGFB3, SMAD2, SMAD3, ACTA2, MYH11, and related genes (F006). Key points: - In an 810-patient H-TAD panel study (Overwater et al. 2018), pathogenic/likely-pathogenic variants were found in 8.1%, of which 9.1% were CNVs undetectable by routine NGS — supporting inclusion of deletion/duplication (CNV) analysis (F006). - The severe homozygous TGFB3 case was identified specifically by "sequence analysis and deletion/duplication testing," which revealed the exon 2–7 deletion (F006). - WGS/WES and targeted panels are all appropriate; single-gene TGFB3 testing is reasonable when the phenotype is highly specific. HTAADVar provides automated ACMG/AMP interpretation (sensitivity 92.6%, specificity 70.8%; PMID 36194209).

Clinical / imaging work-up: - Echocardiography for aortic-root and mitral-valve assessment (aortic root dilatation ~29%, mitral valve disease ~32%). - CT/MR angiography of the entire arterial tree (aortic and head-and-neck vessels) to assess aneurysm and tortuosity — notably, tortuosity is characteristically absent in LDS5 (F011). - Skeletal and craniofacial examination for marfanoid/LDS features.

Differential diagnosis: Marfan syndrome (distinguished by ectopia lentis, absent in Rienhoff), other LDS subtypes (LDS1–4, LDS6), Ehlers-Danlos syndrome (vascular type, COL3A1), and FBN1-related aortopathy. Genetic testing is decisive because clinical features overlap heavily (F006; PMID 29270370).

Biomarkers / omics diagnostics: No validated circulating biomarker, transcriptomic, proteomic, or metabolomic diagnostic exists for Rienhoff syndrome specifically. Diagnosis is molecular + imaging-based.

Screening: Cascade genetic testing of at-risk relatives once a familial variant is identified; no population newborn screening applies.

11. Outcome / Prognosis

Survival / mortality. Prognosis is largely determined by aortic/arterial disease, which in LDS5 is milder and later than in classic LDS. In the Marsili cohort, no deaths occurred from cardiovascular events or pregnancy (F002). Adult LDS surgical series confirm that aggressive management yields good survival despite serious aortic pathology (F004; PMID 25678502: 7/11 experienced type A dissection and all required aortic root replacement — data from broader LDS, not TGFB3-specific).

Morbidity. Driven by aortic surgery, mitral valve disease, skeletal/craniofacial features, and potentially the allergic/immune comorbidities of the TGF-β spectrum (F010). Extra-aortic arterial-aneurysm burden is the lowest among LDS genes (only 3 aneurysms in 3 patients with TGFB3 variants across a 103-patient LDS cohort; F005).

Complications: aortic dissection/rupture (late), need for prophylactic aortic-root replacement, mitral regurgitation, arch/cerebral aneurysms (median dx age ~40 y; F005).

Prognostic factors: presence and rate of aortic-root dilatation, family history of dissection, biallelic (homozygous) status (worse), and hemodynamic risk factors (hypertension, smoking).

12. Treatment

Management follows the established framework for TGF-β-pathway aortopathy (MFS/LDS spectrum), individualized for LDS5's milder, later cardiovascular course.

Pharmacotherapy (MAXO: drug therapy, MAXO:0000058): - Beta-adrenergic blockers (e.g., atenolol) to reduce aortic-wall stress (MAXO term: administration of beta-adrenergic antagonist). - Angiotensin-receptor blockers — losartan (AT1R antagonist) — mechanistically rationalized by suppression of AngII-dependent TGF-β/Smad2 signaling (F004, F013). Losartan "has the potential to inhibit aortic aneurysm formation." Note: head-to-head trials in Marfan (PMID 25405392) found no significant difference between losartan and atenolol in slowing aortic-root dilatation, so both are used, often in combination. - CHEBI: losartan (CHEBI:6541); atenolol (CHEBI:2904); angiotensin II (CHEBI:2718).

Surgical / interventional (MAXO: surgical procedure): - Prophylactic aortic-root replacement at aortic-diameter thresholds — performed at lower thresholds than in Marfan for the broader LDS spectrum because dissection can occur at smaller diameters (F004). Because LDS5 lacks evidence of early dissection, thresholds should be individualized. - Valve-sparing root replacement / mitral valve repair as indicated. - Endovascular repair (EVAR/TEVAR) is reserved largely for emergent bridging in H-TAD per current guidance (PMID 41759888).

Supportive / rehabilitative: activity/isometric-exertion restriction, blood-pressure control, and management of skeletal/craniofacial features (orthopedic, cleft-palate repair when present).

Pharmacogenomics. In Marfan, ADRB1-rs1801253 genotype associated with atenolol response (PMID 32586526) — an allied-disease finding that may inform beta-blocker selection but is not Rienhoff-validated.

Experimental / advanced therapeutics. No gene, cell, or RNA-based therapy exists for Rienhoff syndrome; management remains hemodynamic/surgical. TGF-β neutralization has shown context-dependent (timing-sensitive) effects in MFS mouse models (PMID 25614286), cautioning against naive pathway blockade.

13. Prevention

Primary prevention: not possible for the genetic disorder itself; genetic counseling and reproductive options (prenatal/preimplantation genetic testing) for known familial variants.
Secondary prevention: cascade genetic testing of relatives; early imaging surveillance to detect aortic dilatation before complications.
Tertiary prevention: beta-blockers/ARBs, blood-pressure and lifestyle control, activity modification, and timely prophylactic aortic surgery to prevent dissection/rupture (F004, F013).
Counseling: autosomal dominant recurrence risk (50% for heterozygous carriers); emphasize incomplete penetrance and variable expressivity, and the more severe outcome of biallelic inheritance (relevant in consanguineous unions) (F007).
Public health / environmental: smoking cessation and hypertension control reduce arterial-event risk (Calderon-Martinez 2025).

14. Other Species / Natural Disease

Taxonomy / orthologs: TGFB3 is conserved across mammals; mouse Tgfb3 (NCBI Gene ID 21809) is the principal ortholog used experimentally. Species affected experimentally: Mus musculus (NCBI:txid10090).
Natural disease: No well-characterized naturally occurring "Rienhoff syndrome" analog is documented in companion animals or wildlife (no OMIA entry established in the reviewed literature). This is a knowledge gap.
Comparative biology: the essential developmental role of Tgfb3 in palatal fusion and cardiovascular development is evolutionarily conserved (F003, F012), making the mouse a faithful model of the craniofacial arm.
Zoonotic potential: not applicable (non-infectious genetic disorder).

15. Model Organisms

The principal model is the Tgfb3-null mouse (F012): - Phenotype recapitulation: Tgfb3 homozygous-null mice develop isolated cleft of the secondary palate with 100% penetrance, caused by failure of the paired palatal shelves to fuse (shelves elevate and appose normally, but the medial-edge epithelium fails to break down/adhere). Liu et al. 2020: "Tgf-β3 plays a critical role in regulating murine palate development, and Tgf-β3 null mutants develop cleft palate with 100% penetrance." Ozturk et al. 2013: "TGFβ3-null mice exhibit CP without any other major deformities." - Isoform specificity: Yang & Kaartinen 2007 showed that knocking Tgfb1 into the Tgfb3 locus only partially rescues the fusion defect, demonstrating a TGF-β3 isoform-specific role in palatal epithelial fusion (F012). - Mechanism captured: the TGFβ3→IRF6→ΔNp63 periderm-removal pathway (Hu et al. 2015). - LDS knockin models: Tgfbr1/Tgfbr2 LDS knockin mice recapitulate the human aortic phenotype and demonstrate the AngII/losartan/Smad2 mechanism (Gallo et al. 2014, F013) — these model the aortopathy arm (though for receptor genes, not TGFB3 specifically).

Model limitations: the Tgfb3-null mouse models the craniofacial (cleft-palate) arm but not the adult aortopathy of Rienhoff syndrome. No published mouse carries the human coding TGFB3 missense alleles to model the full systemic connective-tissue phenotype — a significant gap. Resources: MGI (mouse), and TGF-β knockin lines from LDS aortopathy studies.

Mechanistic Model / Interpretation

Rienhoff syndrome is best understood as a TGF-β signaling dysregulation disorder with a dual anatomical footprint — a developmental (craniofacial/skeletal) arm and a progressive (cardiovascular) arm — unified by perturbed TGFB3 function but diverging in timing and mechanism.

    TGFB3 pathogenic variant (heterozygous; rarely biallelic)
                       │
  ┌────────────────────────────┴────────────────────────────┐
  v                                                          v
 DEVELOPMENTAL ARM (congenital)                     CARDIOVASCULAR ARM (later-onset)
 Loss of TGF-b3 ligand function                     Paradoxically INCREASED aortic
  │                                         TGF-b / SMAD2 signaling
  v                                               │   ^
 Failed palatal MEE fusion                                │   │ amplified by
 (TGFb3->IRF6->dNp63 periderm removal)                    │   │ AngII / AT1R
  v                                               v   │ (hemodynamic stress)
 Cleft palate / bifid uvula /                     Medial degeneration, elastin
 high-arched palate; marfanoid                    fragmentation, MMP activity
 skeleton (arachnodactyly, pectus,                        │
 joint laxity)                                            v
                                 Aortic root dilatation -> aneurysm
                                 -> (LATE, ~50s) dissection
                                 Low extra-aortic aneurysm burden;
                                 NO tortuosity; NO ectopia lentis

Two features distinguish LDS5/Rienhoff from its LDS siblings and from Marfan: (1) it has the lowest extra-aortic arterial-aneurysm burden among the five LDS genes and lacks striking arterial tortuosity, and (2) it lacks ectopia lentis, the hallmark of Marfan. The therapeutic corollary of the "paradoxically increased signaling" model is that AngII/AT1R blockade (losartan) is rational because it suppresses the SMAD2 axis that drives postnatal aneurysm growth. The bidirectional stature effect and the codon-300 hotspot indicate that different TGFB3 alleles tune signaling output in different directions while sharing a core connective-tissue phenotype.

Evidence Base

PMID	Title (abbrev.)	Supports	Contribution
26184463	Exome sequencing identifies novel heterozygous TGFB3 mutation…	F001, F014	Defines p.Arg300Gly, codon-300 hotspot, bidirectional stature, "increased TGF-β signalling"
31898322	Phenotypic spectrum of TGFB3 variants (Dutch-French cohort)…	F002, F007	Largest cohort; phenotype frequencies; incomplete penetrance; homozygous severity
32022420	Homozygous deletion of exons 2-7 within TGFB3…	F003, F006, F008	Gene-dosage effect; equates TGFB3 with LDS5 + ARVD1; diagnostic method
18257072	Tissue-specific Cre from the Tgfb3 locus	F003	Tgfb3 "absolutely required for normal palatal fusion and pulmonary development"
27181042	Pathophysiology & Management of CV Manifestations in MFS/LDS	F004, F013	AT1R/losartan therapeutic rationale
25678502	Adult surgical experience with Loeys-Dietz syndrome	F004	Aggressive aortic pathology; surgical management
40533122	Characterization of Arterial Aneurysms in LDS	F005	TGFB3 has fewest extra-aortic aneurysms among LDS genes
29907982	NGS gene panel incl. CNV analysis in 810 H-TAD patients	F006	8.1% yield; 9.1% CNVs; supports panel + CNV testing
15639475	Regulatory TGFB3 mutations cause ARVD1	F009	UTR gain-of-function → allelic ARVD1
23884466	TGFβ receptor mutations predispose to allergic disease	F010	Immune/allergic axis of TGF-β-pathway LDS
24355923	AngII-dependent TGF-β signaling in LDS vascular pathogenesis	F013	Losartan efficacy ↔ Smad2 suppression in LDS mice
32913205	Transcriptional analysis of cleft palate in TGFβ3 mutant mice	F012	Tgfb3-null cleft palate 100% penetrant
23421592	RNA-Seq of TGFβ3-knockout palate	F012	Isolated CP without other major deformities
17967447	Tgfb1 knock-in partially rescues Tgfb3 cleft palate	F012	TGF-β3 isoform-specific palatal fusion role
25405392	Atenolol vs losartan in Marfan (PHN trial)	§12 (allied)	No significant difference in aortic-root dilatation rate
29270370	Differences among MFS, EDS, LDS	§10 (context)	Phenotypic overlap necessitating genetic testing

Consistency: Findings are mutually reinforcing. The cohort study (31898322), the homozygous case report (32022420), and the allelic-series paper (26184463) independently converge on TGFB3→LDS5, gene-dosage severity, and the codon-300 hotspot. The mouse literature (18257072, 32913205, 23421592, 17967447) consistently establishes the palatal-fusion mechanism. The therapeutic mechanism is supported by both a mouse mechanistic study (24355923) and a clinical review (27181042).

Challenges/nuance: The Marfan atenolol-vs-losartan trial (25405392) found no significant superiority of losartan, and TGF-β neutralization in MFS mice had timing-dependent (sometimes harmful) effects (25614286) — cautioning that the "paradoxical TGF-β increase" model does not translate to simple pathway blockade as therapy.

Limitations and Knowledge Gaps

Ultra-rarity. Only ~30–60 families reported; no prevalence, incidence, sex-ratio, penetrance quantification, or geographic/founder data exist. Phenotype frequencies rest largely on a single 32-patient cohort.
No TGFB3-specific natural-history or QoL data. Prognostic and quality-of-life statements borrow from the allied Marfan/LDS literature.
The signaling paradox is incompletely resolved at the TGFB3-specific level; most mechanistic aortic data derive from Tgfbr1/2 and Fbn1 models, not TGFB3 knock-in mice.
No TGFB3 coding-allele mouse recapitulating the full systemic phenotype; the null mouse models only the craniofacial arm.
Therapeutics are not disease-specific or trial-validated in LDS5; management is extrapolated from MFS/LDS, where even losartan's benefit is contested.
Immune/allergic axis (F010) is demonstrated for receptor-based LDS, not directly for TGFB3/Rienhoff patients.
No epigenetic, proteomic, metabolomic, or single-cell data specific to Rienhoff syndrome.
No documented natural animal disease / OMIA entry.

Proposed Follow-up Experiments / Actions

Build a TGFB3 knock-in mouse carrying human alleles (e.g., p.Arg300Gln/Gly, p.Cys409Tyr) to model the full systemic phenotype, directly test the "paradoxically increased aortic TGF-β/SMAD2 signaling" hypothesis, and evaluate losartan/beta-blocker response — including the bidirectional stature effect.
Establish an international TGFB3/LDS5 registry to generate true penetrance, natural-history, dissection-risk, and diameter-threshold data for surgical timing tailored to LDS5's milder course.
Phenotype the allergic/immune axis prospectively in TGFB3 patients (IgE, eosinophils, TH2 skewing) to confirm whether the LDS allergic predisposition extends to Rienhoff syndrome (F010).
Genotype–phenotype correlation study across the TGFB3 allelic series (LoF vs codon-300 vs biallelic) using functional signaling assays (SMAD2 phosphorylation in patient fibroblasts/iPSC-derived VSMCs).
Aortic-tissue multi-omics (transcriptomics/proteomics on surgical specimens) to define TGFB3-specific molecular signatures and candidate circulating biomarkers.
Evaluate CNV-inclusive panel testing uptake to ensure structural TGFB3 variants (like the exon 2–7 deletion) are not missed diagnostically (F006).
iPSC-derived vascular smooth muscle cell and cranial neural-crest models from patients to dissect the divergent developmental vs cardiovascular mechanisms in a human context.

Evidence-source legend: human clinical (cohort/case reports, surgical series); model organism (mouse Tgfb3-null and LDS knockin); in vitro/computational (UTR reporter assays, variant-interpretation frameworks). Findings F001–F014 correspond to the confirmed knowledge state from this investigation.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Rienhoff Syndrome — Comprehensive Disease Characteristics Research Report

1. Disease Information

2. Etiology

3. Phenotypes

Musculoskeletal / Growth

Craniofacial

Cardiovascular

Other

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Citations

Key Findings

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

Artifacts